Shortlist of significantly modulated upstream regulators during the early stage of ASML cell rat liver colonization.
\n
Based on this analysis, the category “cellular movement” with the two function annotations “cell movement of mononuclear leukocytes” and “migration of phagocytes” with 121 and 80 genes, respectively, was significantly increased at early and terminal stages, but not significantly altered at intermediate and advanced stages. This is surprising, as it shows that movement or migration of cells is not equally important over the whole colonization period. Although this category of genes is increased initially, soon thereafter it is deactivated and reactivated only for the terminal stage (Table 1, top part, column 1).
\nAnother example is the category of genes related to proliferation. As could be expected, genes belonging to this category were augmented in expression initially, as derived from the significantly increased activation z-score (2.44), but failed to show activation at intermediate and advanced stages. At these stages, genes related to neuronal cell proliferation were even decreased in expression or showed no activation. At the terminal stage, there was activation of genes related to the proliferation of fibroblasts, but not of genes related to proliferation of neuronal cells (Table 1, top part, column 2).
\nGenes related to the growth of connective tissue, fatty acid metabolism, M-phase of tumor cell lines, and quantity of myeloid cells were mainly upregulated but not throughout the whole liver colonization process. In addition, genes related to the immune response, phagocytosis, and invasion were decreased in activation (Table 1, top and bottom parts, columns 3–9).
\n\nSubsequently, Ingenuity Pathway Analysis (IPA) was used for overlaying the findings of this study onto scaffolds of known genetic relationships. This included a scaffold for the genes of the acute phase signaling chain, which was overlaid with gene expression levels obtained at intermediate (day 6 after tumor cell implantation, Figure 3A) and terminal (day 21 after tumor cell implantation, Figure 3B) stages.
\nThese figures show a differentiation of genes according to cellular compartments as well as to colors as indicator of expression levels. Symbols, which have been placed to the specific cellular or extracellular sites of the respective proteins, are used to report on a specific gene expression. A colored border line of the respective symbol indicates that data from the present analysis were available to describe the status of the gene. The colors used for filling the symbol denote differences in expression: red color indicates increased expression and green color indicates decreased expression, with less intense colors hinting to less pronounced increased or decreased expression.
\nOn day 6 after tumor cell implantation, two genes (albumin and transferrin) of the acute phase signaling chain are highlighted in intense red color and three genes (interleukin 6, α-2-macroglobulin, and ceruloplasmin) in intense green color. Fifteen more genes are shown by red colors of lower intensity, indicating submaximally increased expression levels. In addition, 14 genes are highlighted in a green color of reduced intensity, indicating less than maximally decreased expression (see Figure 3A).
\nAt the terminal stage, eight genes (albumin, transferrin, α-1-microglobulin, fibrinogen alpha chain, serpin family A member 3, inter-alpha-trypsin inhibitor heavy chain H3, inter-alpha-trypsin inhibitor heavy chain H4, and coagulation factor II (thrombin)) were highlighted in the most intense red color and 21 more genes in less intense red colors. Concomitantly, only 1 gene (interleukin 6) was highlighted in intense green color and 15 in less intense green colors (see Figure 3B), indicating a shift from reduced expression of acute phase signaling genes at the intermediate stage to increased expression at the terminal stage of liver colonization.
\nIn addition to using genes of the acute phase signaling as scaffold, another overlay of was done by IPA analysis at the terminal stage of liver colonization for the three signaling cascade scaffolds known as “metastatic solid tumor,” “metastasis,” and “metastatic gastrointestinal tract cancer” (Figure 4). Because of the large overlap between the corresponding genes, all three scaffolds were combined in one scheme, resulting in a picture, in which the three scaffold designations are connected with their respective genes by straight lines. For clarity, the gene symbols are arranged according to their cellular site, i.e. extracellularly, in the plasma membrane, in the cytoplasm, or in the nucleus. In addition to the red/green color scheme known from Figure 3A and B, the straight lines are colored by yellow and blue colors, which indicate activation or inhibition of the respective gene products activity. Thus, very often a gene highlighted in a reddish color, which indicates increased expression over control, will be connected with its scaffold designation by a yellow line, indicating activation of the respective group of genes as given for the scaffold designation “metastatic solid tumor” and the gene expression of collagen, type IV, alpha 2 (Col4a2), or of coagulation factor II, thrombin (F2). This means that the increased expression of Col4a2 or F2 predicts activation of a significant share of related genes. Conversely, a gene highlighted in green color, which indicates decreased expression versus control, is sometimes connected with its scaffold designation by a straight blue line, indicating inhibition of the respective group of genes, as given for the scaffold designation “metastatic solid tumor” and the gene expression of colony stimulating factor 1 (Csf1) or interleukin 6 (IL-6). This means that the decreased expression of Csf1 or Il6 predicts inhibition of a significant share of related genes.
\nIn addition, a gene symbol colored reddish can be connected to the scaffold designation by a yellow line, indicating that its increased expression is related to inhibition of the corresponding gene group, as for the genes apolipoprotein A1 (Apoa1) and serpin family E member 1 (Serpine1). This means that the increased expression of APOA1 or Serpine1 predicts inhibition of a significant share of related genes. Finally, a gene symbol colored greenish can be connected to the scaffold designation by an orange line, as for the genes superoxide dismutase 3 (Sod3) and TIMP metallopeptidase inhibitor 1 (Timp1). This implies that the decreased expression of Sod3 or Timp1 predicts activation of a significant share of related genes (Figure 4A).
\nAs Figure 4A gives an overview on a multitude of genes being connected to the three signaling cascade scaffolds known as “metastatic solid tumor,” “metastasis,” and “metastatic gastrointestinal tract cancer,” which allowed to show less details, a more complete description of a selection of metastasis genes is given in Figure 4B. This figure shows the respective fold changes in mRNA levels versus control as positive or negative numbers below the corresponding gene symbols.
\nThe third IPA analysis concentrated on upstream regulators, which showed a significant modulation in expression and therefore altered the activation state of a whole series of downstream proteins.
\nFrom the early stage of liver colonization, six genes were selected for detailed analysis. These included member RAS oncogene family-like 6 (Rabl6), which was increased in expression and caused significant activation of downstream target genes, as well as Ras association domain family member 1 (Rassf1), nuclear protein, transcriptional regulator, 1 (Nupr1), and jun proto-oncogene (Jun), which also showed increased expression but caused inhibition of the corresponding downstream molecules (Table 2). Finally, the genes interleukin 1 alpha (Il1a) and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma (Ikbkg) showed decreased expression and caused inhibition of their respective downstream molecules (see Table 2).
\nShortlist of significantly modulated upstream regulators during the early stage of ASML cell rat liver colonization.
Rabl6, member RAS oncogene family-like 6; Rassf1, Ras association domain family member 1; Nupr1, nuclear protein, transcriptional regulator, 1; Jun, jun proto-oncogene; Il1a, interleukin 1 alpha; and Ikbkg, inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma.
From the intermediate stage of liver colonization, also six genes were selected for detailed analysis. These genes included colony stimulating factor 2 (Csf2) and NK2 homeobox 3 (Nkx2-3), which showed decreased expression, but activated their respective downstream molecules. The transcription regulator forkhead box M1 (Foxm1) was increased in expression and activated the corresponding downstream genes. The genes cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1), angiotensinogen (Agt), and secreted phosphoprotein 1 (Spp1) showed increased expression but inhibited their corresponding downstream genes (see Table 3).
\nShortlist of significantly modulated upstream regulators during the intermediate stage of ASML cell rat liver colonization.
Csf2, colony stimulating factor 2; Nkx2-3, NK2 homeobox 3; Foxm1, forkhead box M1; Cyp2e1, cytochrome P450, family 2, subfamily e, polypeptide 1; Agt, angiotensinogen; and Spp1, secreted phosphoprotein 1.
From the advanced stage of liver colonization, four genes were selected for detailed analysis. These genes included Versican (Vcan), which showed a reduced expression but activated its downstream genes, as well as myelocytomatosis oncogene (Myc), which exhibited increased expression and also activated a considerable number of downstream genes. The genes CCAAT/enhancer-binding protein beta (Cebpb) and transforming growth factor, beta 1 (Tgfb1), on the other hand, were reduced in expression and as a result inhibited their respective genes (Table 4).
\n\x3c!--Upstream regulator (advanced stage) | \nExp. fold change | \nMolecule type | \nPredicted activation state | \nActivation z-score/p value of overlap | \nTarget molecules in Ingenuity Pathway Analysis dataset | \n
---|---|---|---|---|---|
Vcan | \n−4.25 | \nOther | \nActivated | \n2.823/5.37E−18 | \nADM,AEBP1,ANG,ASS1,C1R,C1S,Calm1, CASP1, Ccl2, CCL20,CEBPB, CIDEA,CPE,CXCL2,CYBA,FABP5,FAS, FST, ICAM1,LGALS9B, Mecom, METRNL,NFKB1, NFKBIA,PLA2G2A, PRDX5, RBP1, SERPING1, Slpi, SOD2, TGFB1, TIMP1, VCAM1, VCAN,VEGFA, Wfdc17/Wfdc18 | \n
Myc | \n2.57 | \nTranscription regulator | \nActivated | \n2.907/3.06E−20 | \nADK,ADM,ALB,ALDH18A1,ARG1,ASS1,AURKB,BCL6,BIN1,BIRC5, CASP1, CCNA2,CCNB1,CCND2,CD151,CD19, CDC20,CDCA7, CEBPD, CITED1, CKS2,COL2A1,COL3A1,COL5A2,CPD,CPT1A,CSPG4,CSRP2,CTSB,CTSD,DDIT3, DDX39B,DHFR,DUSP5,EBI3,EDN1,EFEMP1, EMP1, EPHA2, FABP5, FAS,FGFR1,FMOD,FOS, FOXE1, FTH1,G6PD,GAA,GADD45B, GADD45G, GAMT,Gar1,GBP2,GBP4,GCLC, GJA1,H19,HES1,HIVEP2,HLA-A, HMOX1, ICAM1, ID1, IDH1, IDH2, IER3, INHBA, ITGA6, JUN, KDR,KLF10, KLF4, KLF6,KRT7,Ptma,LUM,LYZ,MCM7,MGP,MKI67,Mt1,MYC,MYL9, MYLPF, NFKBIA, Nppb, NPY, OPRK1, PDCD4, PLA1A, PLK1, PLP1, PLS3, POLD1, PPL,Ppp1r15a,PSAT1,PTN,RBP1,SCAMP5,SHMT1,SHMT2, SLC22A4, SLC7A5, SMN1/SMN2, SOD2,SPN,STMN1, TAF1D, TF, TGFB1, THBS1, TIMP1,TMSB10/TMSB4X,TXNRD1,VCAM1,VEGFA,VEGFC, VIM, WISP1 | \n
Cebpb | \n−2.51 | \nTranscription regulator | \nInhibited | \n−3.299/1.84E−21 | \nAbcb1b,AKR1B10,AKR1C3,ALB,APLN,ARG1,BLNK,CCL2,Ccl2,CCL3L3 CCNA2,CCND2,CD14,CDC45,CDH3,CEBPB,CEBPD,COL5A2, CP, CPT1A, CSF3,CTSC,CXCL2,CXCR4,CYP11A1,CYP1A1,CYP27B1,DDIT3, DGAT2, DHFR, FAS, FBLN1, FGFR2,FHL2,FOS,FZD1,HDC,HLA-A, HP, ICAM1, ID1,IER3,IFITM3,IKBKE,IL1B,IL6,JUN, KRT18,MGP,MYC,NDRG4, NFKBIZ, NUPR1,PDK4,PEA15, PLA2G4A,PLAC1,PTGS1, SCD, SLC12A2, TF,TGFB1, TMEM176A, TNFAIP6, TNFRSF1A, TRIB3, TUBB3, VCAN, VIM, XDH | \n
Tgfb1 | \n−2.48 | \nGrowth factor | \nInhibited | \n−2.346/6.57E−59 | \nABCA1,ADAMTS4,ADK,ADM,ADORA1,AGTR2,ALB,ALDH18A1,APLN,APOC2,AQP9,ARG1,ASS1,AXL,B3GALT2,BARD1, BCL3,BCL6, BGN, BIN1, BIRC5,BMP7,C1QA,C1QB,C1S,Calm1, CALML4, CAMP,CARS, CASP1, CAT,CBR3,CCL2,Ccl2,CCL20, CCL3L3,CCNA2,CCNB1, CCND2, CD14, CD36, CD68, CDC20, CDH11, CEBPB, CENPF,CITED2, CKS2, CLDN4, CMTM5, COL18A1, COL2A1, COL3A1, COTL1, CREB3, CSF1, CSPG4, CSRP2, CST3, CTGF,CTSB, CTSC, CTSD,CTSS,CX3CR1, CXCL2, CXCR4, CYBA,CYP11A1,CYP27B1, CYP3A7, DFNA5, DNMT3A, EDN1, ELF3, ELK3, ENPP1, EPHA2, ESPL1, EXT1, FABP5, FAM110B, FAS, FCER1G, FDXR, FGF2, FGF21, FGFR1,FGFR2,FOS,FSTL3,FTH1, FXYD5, FZD1, GADD45B, GATA3,GBP2,GCLC,GDF15,GJA1,GLCE,GLI1, Gsta4, GSTA5, GTPBP1, H6PD,HEBP1,HES1,HLA-DQB1, HMOX1, HPGD, HSPA1A / HSPA1B, HTRA1, ICAM1, ID1, IER3, IFRD1,IGF2, IGFBP2, IGFBP5, IGFBP6, IL11, IL13RA2, IL18,IL1B, IL33,IL6,IL6R,INHA, INHBA, IRAK3, ITGA1, ITGA6, ITGB6, JUN, KDR, KLF10,KLF15, KLF4, KRT18,KRT7,LITAF,LOXL1, LPAR1, MAOA,MFAP2,MGP, MKI67, MMP12, MSMO1, MTHFD2, MYBL1, MYC, MYD88,MYLK,MYLPF, MYO10, NAB2, NDC80, NDRG4, NFKBIA, NNMT, NOV, NPR1, NR4A1, NR4A3, NT5E,NUPR1,OSR2,P2RY6,PAPPA, PARP3, PDCD4,PDE4D,PGRMC1,PLA1A, PLA2G4A, PLAGL1, PLS3, PLXNC1, PNOC, POLD1, PPFIBP2, PPP1R13B, PPP1R3C, PRC1,PTGS1, PTK2B, PTPN6,RAB31, RACGAP1, RAPGEF3, RASGRP3, RASL11B,RASSF1, RBPMS, RHOD, S100A11, S100A4, SBNO2, SCD, SDC4, SEMA3A, SEMA3B, SFTPC, SHMT1, SHOC2, SLC7A5, SMC4, SNAI2,SOD2, SOD3, SPC25,SPEG,SPHK1,SRFBP1,TBX3,TCF12,TGFB1, TGM2, THBS1, TIMP1, TJP2, TLR2, TLR4,TNFAIP6, TNFRSF12A,Tpm2,TUBB2A,TUBB3, TXNRD1, VCAM1, VCAN,VEGFA, VEGFC,VIM, WFS1, WISP1,WNT11, WT1, XDH | \n
Vcan, Versican; Myc, myelocytomatosis oncogene; Cebpb, CCAAT/enhancer-binding protein beta; and Tgfb1, transforming growth factor, beta 1.
\nShortlist of significantly modulated upstream regulators during the advanced stage of ASML cell rat liver colonization
\nShortlist of significantly modulated upstream regulators during the advanced stage of ASML cell rat liver colonization
Vcan, Versican; Myc, myelocytomatosis oncogene; Cebpb, CCAAT/enhancer-binding protein beta; and Tgfb1, transforming growth factor, beta 1.
Shortlist of significantly modulated upstream regulators during the terminal stage of ASML cell rat liver colonization.
Csf2, colony stimulating factor 2; Foxm1, forkhead box M1; Tsc2, tuberous sclerosis 2; and Tnf, tumor necrosis factor.
From the terminal stage of liver colonization, again four genes were selected for detailed analysis. These included two genes, which had been listed before (Csf2 and Foxm1) that caused the same pattern of expression and resulting influence as in the intermediate stage of liver colonization (decreased expression but subsequent activation in the case of Csf2 and increased expression resulting in subsequent activation in the case of Foxm2). The other two regulators (tuberous sclerosis 2 (Tsc2) and tumor necrosis factor (Tnf)) were both increased in expression and were predicted to inhibit a large number of downstream genes (see Table 5).
\n\x3c!--Upstream regulator (terminal stage) | \nExp. fold change | \nMolecule type | \nPredicted activation state | \nActivation z-score/p value of overlap | \nTarget molecules in Ingenuity Pathway Analysis dataset | \n
---|---|---|---|---|---|
Csf2 | \n−2.81 | \nCytokine | \nActivated | \n2.752/3.11E−35 | \nSee | \n
Foxm1 | \n2.54 | \nTranscription regulator | \nActivated | \n2.751/2.02E−11 | \nSee | \n
Tsc2 | \n3.08 | \nOther | \nInhibited | \n−2.551/1.78E−12 | \nA2M,ACSS2,ANXA1,ATF3,B3GALT2,BIRC5,Ccl2,CCND2,CCND3,DDIT3, DYNC1I1,EGR1,GPNMB, HMGCS2,HMOX1,IRS1,MGP, NSDHL, PDGFRA, PDGFRB,PRELP,RASSF4,S100A11,S100A6,SCD,SLC2A1, SMPDL3A, SOD2, TAGLN, TMEM176A, TMEM176B, VAMP8 | \n
Tnf | \n3.53 | \nCytokine | \nInhibited | \n−2.209/3.74E−86 | \nA2M,A4GALT,Abcb1b,ABCC3,ACP5,ACSL1,ADAMTS4,ADM,ADORA1,ADORA2A,AEBP1,AGT, AGTR1, AKR1B1, AKR1B10,ALB,ANGPT2, ANGPTL4, ANXA1,AOC3,APCS,APOA1,APOC2,APOC4,APOE,AQP1,AQP3,AQP9, ARG1,ARHGDIB,ARL6IP5,ARRDC3,ASGR1,ASS1,ATF3,AXIN2, B4GALNT1, B4GALT1, BACE1, BCL2A1, BCL3, BCL6, BID, BIK, BIRC5, BMP2, BTG2, BUB1B, C5AR1,CASP8,CAT, CCDC80,CCL19, CCL2,Ccl2, CCL20, CCL3L3, CCL4, CCL5,Ccl6,CCND2,CCND3,CCR1,CCR5,CCR6,CD14,CD163, CD247, CD40,CD82, CDH1, CDH11, CDH2, CEBPD, CFB, CFD, CFLAR, CH25H, CLDN4, COL1A2,COL3A1, COTL1, CPT1A,CREB3, CREB3L3, CSF1, CSF3, CTGF, CTSK, CTSS, CTSZ, CXCL12, CXCL13, CXCL2, Cxcl9, CXCR4, CYBA, CYBB,CYLD, CYP1A1, CYP1B1, CYP26B1,CYP2C8,CYP2E1,CYP7B1, CYTIP, DCBLD2, DCHS1, DCN, DDIT3,DENND2D, DPP4,DPYS,DUSP1, DUSP2, DUSP5, DUSP9,EBI3,EDN1,EDNRB, EFNA1, EGFR,EGR1, EGR2, EIF2AK2, ELF3, ELK3, EMP1, ENPP3, ENTPD5, EPHA2, ERG, ESM1,EXT1, F3,FABP1, FABP4, FADS1, FAM132A, FAM198B, FAS, FCER1G,FCGR2B, FDPS, FGF2, FGFR1, FGG, FOSL1,FOXE1,FRMD6,FRZB, G0S2,GADD45B,GCH1, GCLC, GDF15,GDNF, GPD1, GPR176, GPRC5B,GPX1, Gsta4, GSTP1, H19, HDC, HERC1,HES1,HID1,HK3,HLA-DRA,HMOX1,HP,HPGD,HSD11B1, HSD17B7, HSPA1A/ HSPA1B,ICAM1, ICAM2, ICOS, ID1, ID3,IDH2, IER2, IER3, IFIH1, IFIT3, IGF1, IGF2, IGFBP1, IGFBP2, IGFBP3, IGFBP5, IKBKE, IL11, IL16, IL18, IL1B, IL1R2, IL23A, IL24,IL3RA, IL6,INHA,INPP5D,IRAK3,IRF5, IRS1, ITGA6, ITGB2, ITGB6,JAG1, KDR, KIF20A, LAMC1,LBP,LCAT,LCN2, LDLR, LGALS8, LOX, LPAR6, LPL, LSS, LTB, LXN,LY96, LYVE1, MAFF, MALL, MAN1C1,MAP3K8,MBL2, MCAM, MEF2C,MET,MFHAS1, MGMT, MGP, MGST1, MMD, MMP12, MSLN, MST1, Mt1,MVP, Mx1/Mx2, MYLK, NCF1, NEFH, NFKB1,NFKB2, NFKBIA, NFKBIZ, NINJ1, NNMT, NOS3, NOTCH4, NOX1, NPM3, Nppb, NQO1, NR0B2, NR1I2, NR4A1, NRP1, OAS1, OCLN, OLR1, OPTN, ORM1, P2RX5,PCK1, PCSK6,PDE2A, PDGFA, PDGFRA, PDIA4, PENK, PER2, PIM3, PLA2G3, PLA2G4A, PLAUR, PLK2, PLK3, PLOD2, PLP1, PLVAP, POMC, POSTN,PPARG, PPP1R3C, Prl2c2, PRNP, PRSS23, PSMB9, PTGS1, PTPRC, PTPRN,RAB32,RARRES2, RBP1, RFTN1,RGCC, RGS1, RGS2, RGS20, RGS4, RGS5, RGS9, RND1, ROBO1, S100A8, S100A9,SCD,SDC2,SDC4, SEMA3C,SEPP1,SERPINA3, SERPINB1, SERPIND1,SERPINE1,SERPINE2,SGK1,SHBG,SLC10A1,SLC11A1, SLC11A2, SLC1A4, SLC22A4, SLC27A5, SLC2A1, SLC2A2, SLC7A2,SLC7A8, Slco1a1, Slco1a4, SMPD1, SMPD2, SMPDL3A, SNN,SOAT1,SOD2, SOD3, SPARC, SPHK1, SPP1, SPSB1, SQSTM1,ST3GAL6,STMN1,SYNPO,TAGLN, TBXAS1, TF,TGFB1,TGFB2,TGFB3,TGM2,THBS1,THBS2,TIMP1,TK1,TLR2, TLR3, TMEM176B, TNF, TNFRSF11B, TNFRSF1A,TNFRSF21, TNNC1, TPST1, TRAF3,TRPC6,TXNIP,TXNRD1,UBD,VCAM1,VMP1,XIAP, ZC3H12A | \n
Csf2, colony stimulating factor 2; Foxm1, forkhead box M1; Tsc2, tuberous sclerosis 2; and Tnf, tumor necrosis factor.
\nShortlist of significantly modulated upstream regulators during the terminal stage of ASML cell rat liver colonization.
\nFor assessing the influence of the environment on ASML tumor cells, ASML cells were also recultivated in vitro for 3, 6, and 9 days after they had been reisolated from rat liver after a colonization period for 21 days. As a result, genes were found to be downregulated in vitro or upregulated at varying degrees. Some examples are given in Figure 5. As can be seen, the genes desmoglein 4 (Dsg4), tRNA methyltransferase 10A (Trmt10a), and stathmin 2 (Stmn2) were decreased more than 1000-fold, more than 100-fold, and more than 3-fold, respectively. In contrast, the genes apolipoprotein C-II (Apoc2), ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1), and Keratin 18 (Krt18) were increased more than 3-fold (Apoc2 and Enpp1) and more than 100-fold (Krt18). The differences between the cultivation periods of 3, 6, and 9 days were very low and thus negligible.
\nChanges in mRNA expression after recultivation in vitro: ASML cells were also recultivated in vitro for 3, 6, and 9 days after they had been reisolated from rat liver after a colonization period for 21 days. As a result, some genes were downregulated or upregulated in vitro, at varying degrees. Seven examples are given in comparison to control.
Concomitantly with the mRNA species, all known miRNA molecules were analyzed in the respective batches of reisolated ASML cells. As for the distribution of mRNAs, the modulation of miRNA expression was detailed for the two same categories, i.e. the fold changes in miRNA expression and the respective stage of liver colonization, as shown in Figure 6.
\nmiRNA modulation of rat pancreatic cancer cells colonizing rat liver: Given is the fold change of mRNA expression of reisolated ASML cells during early, intermediate, advanced, and terminal stages of liver colonization relative to control cells growing in vitro.
Because of the lower number of existing miRNAs as compared to mRNAs, the distribution looks not as bell shaped as for mRNAs in Figure 1. This is also due to a considerable number of miRNAs, which show a more than 20-fold regulation (both, positive and negative) in the terminal stage of liver colonization.
\nAn example for the influence of miRNAs is given in Figure 7. The miRNA 29b-3p is known for its effect on extracellular matrix proteins, as on collagens [17]. Downregulation of miRNA 29b-3p was observed in ASML cells during the whole period of liver colonization. This is shown in Figure 7A, with the nadir of miRNA 29b-3p expression appearing on day 3 (less than 10-fold of control level), and some recovery thereafter to a plateau of expression ranging from fivefold to threefold reduced levels, as related to control expression in vitro. This reduction was associated with distinctly increased expression of the collagens Col4a2 (collagen, type IV, alpha 2), Col3a2, Col1a2, Col1a1, and Col4a1. Col5a3 showed only a minor increase in expression, but Col5a2 (collagen, type V, alpha 2) showed reduced expression, as was true for Tgfb3 (transforming growth factor, beta 3) (Figure 7B).
\nInfluence of miRNA 29b-3p on gene expression: Shown is the expression of miRNA 29b-3p in ASML cells during liver colonization (
This analysis shows that certain extracellular matrix proteins, as the collagen family, are highly regulated by their respective miRNA. Further experiments are needed to reveal the mechanistic role of these proteins during liver colonization and to address the question whether they can be diagnostic or therapeutic targets.
\nChildhood autism is more prevalent than childhood cancer, juvenile diabetes and pediatric AIDS combined, with an estimated prevalence of 3 M children in Europe, 1.5 M in the US, and tens of millions throughout the rest of the world. More disturbing is that for no explicable reason childhood autism appears to be increasing at a rate of 10–17% per year [1]. Typically displayed in early childhood, autism may be associated with many co-morbidities that include epilepsy, attention deficit/hyperactivity disorder (ADHD), abnormal sensory or motor responses, disturbed sleep, reduced cognitive functionality, anxiety and aggression [2, 3, 4], or none at all.
In 2019 the CDC reported the rate of autism in the US to be 1 in 59 children, with boys being 4 times more susceptible than girls [5]. This means that 1 in 42 boys are diagnosed with autism. There was an increase of about 30% since the assessment of autism prevalence conducted previously (Table 1), and more almost 3x the rate that was reported only 20 years ago. In New Jersey the observed rate of autism was 1 in 46 children, which means that 1 in 29 boys born in New Jersey are likely to be autistic [6, 7].
Identified Prevalence of Autism Spectrum Disorder | ||||
---|---|---|---|---|
ADDM Network 2000-2010 | ||||
Combining Data from All Sites | ||||
Surveillance Year | Birth Year | Number of ADDM Sites Reporting | Prevalence per 1,000 Children (Range) | This is about 1 in X children… |
2000 | 1992 | 6 | 6.7 (4.5–9.9) | 1 in 150 |
2002 | 1994 | 14 | 6.6 (3.3–10.6) | 1 in 150 |
2004 | 1996 | 8 | 8.0 (4.6–9.8) | 1 in 125 |
2006 | 1998 | 11 | 9.0 (4.2–12.1) | 1 in 110 |
2008 | 2000 | 14 | 11.3 (4.8–21.2) | 1 in 88 |
2010 | 2002 | 11 | 14.7 (5.7–21.9) | 1 in 68 |
CDC: Prevalence of autism in the US [5].
The lifetime cost of raising an autistic child was estimated in 2014 to be $3.2 M more than the cost of raising a non-autistic child [8], and this does not take into account the societal costs of maintaining these this population as adults once their families are no longer able to do so. The societal costs of autism are broad and deep, and many have never been explored. For example, it was only in mid-2017 that information was developed on the rate of healthcare utilization by autistics and it was found that their need for psychiatric care as well as care for the high incidence of autism associated comorbidities was far beyond that of the general population or other elements of the psychiatric patient population [9]. Similarly, it was not until September of 2017 that the rate of school suspension and expulsion was dramatically higher in the autistic population, and growing as the autistic population grew in numbers [10].
Recently, attention has been brought to bear on autism associated mortality rates. Although autism is not typically considered to be a fatal disease, several investigators have reported a significantly increased mortality in the autistic population with the major cause of death being suicide. A matched case cohort study based upon the Swedish National Patient Registry and the Cause of Death Registry looked at deaths between 1987 and 2009 and found a 256% greater death rate in autistic patients compared to the general population. The mean age at the time of death was 70.2 years for the general population and 58.39 for patients with autism, with suicide associated with better performing patients [11]. A review of 1706 children and adolescents reported an 18% increased risk of suicidal ideation or attempts in autism [12]. 35% of patients with Asperger’s syndrome were reported in a Canadian study t have attempted suicide [13]. Similarly, in Japan [14], Australia [15], England [16], and Belgium [17]. In a French review of the PubMed literature it was found that overall 21.3% of autism patients reported suicidal ideation or had attempted suicide, with the noteworthy observation that “… the methods used are often violent” [18].
Autism is quite heterogenous and has a broad pallet of potential symptoms. These symptoms transcend established investigative disciplines including behavioral studies, developmental studies, neurology, pharmacology and so forth. No truly workable definition of autism has yet emerged to define this heterogenous constellation of symptoms. Theories regarding the causes of autism include impairments within the autonomic nervous system [19], cerebellar dysfunction [20], mitochondrial impairment [21], exposure to toxins [22], and many others.
The autonomic nervous system has been implicated in symptoms that resemble those seen in autism. ASD has been associated with abnormal findings in autonomic related structures including the insula [23, 24] and the amygdala [25, 26, 27]. Autonomic related changes such as increases in basal heart rate [28, 29, 30, 31] and diminished heart rate variability due to psychosocial challenges [32, 33] are seen in autism. The autism-autonomic linkage is exemplified by the consequences of respiratory sinus arrhythmia (RSA) that includes difficulties with socialization [30, 34], language difficulties [34, 35], and delays in cognitive development [35].
Kushki [19] hypothesized a chronically over activated autonomic system is a correlate of autism based upon the exaggerated levels of anxiety that attend autism [33], physiologic hyperarousal [36, 37, 38], and other correlates. Anxiety is perhaps the greatest co-morbidity associated with autism which may drive other features of the disease [39, 40], and has been associated with central nervous system structures that are linked to autonomic function [41, 42]. Phenotypically autism and anxiety both present with stereotyped repetitive and limited interests, avoidance behaviors and speech problems [43, 44, 45]. The relationship between anxiety and reported autonomic symptoms of elevated heart rate, perspiration, and other sequelae of the “fight or flight” reaction reveal a role for the peripheral nervous system function in autism [36, 37, 38]. However, this may be secondary to central autonomic activation. Central functions may manifest as elevated emotional responsiveness and exaggerated threat perception or diminished inhibition of fear responses [36], which are associated with the central structures mentioned above in which autonomic responsiveness and emotional responsiveness overlap.
There is a considerable body of evidence, which will not be reviewed here, that associates autism with cholinergic function in the central nervous system, specifically with various α-subtype nicotinic receptors, notably in the cerebellum. However, as autonomic function is classically considered to be a balance of cholinergic and catecholaminergic systems, perceived increases or decreases in cholinergic function may be manifestations of change in the dynamic balance of these systems with catecholaminergic tone. It may be possible to effect therapeutic change through manipulation of either acetylcholine-based manipulations or the counterbalancing of dopamine, norepinephrine, or epinephrine mediated mechanisms.
Recent work by Hamilton, et al. [46] who sequenced exomes of families with a history of autism found deficiencies in the human dopamine transporter gene (hDAT), a protein responsible for the presynaptic reuptake of dopamine. CNS dopamine is a crucial element in systems that mediate motor function, motivation, attention and reward [47, 48, 49, 50]. As this system is known to be associated with ADHD, and approximately 45% of autistic patients manifest symptoms of ADHD [3, 51, 52, 53], there is reasons to suspect a common pathway underlying these two diseases. Moreover, dopamine related genes
Other lines of support come from observations of lower levels of dopamine β-hydroxylase in the plasma of autistic patients [64, 65] and reductions in platelet [66] and urine dopamine [67]. Similarly, inferences have been published that the mesolimbic cortex and striatum may provide a neurologic substrate linked with the motor and behavioral symptoms seen in autism as a result of a dopaminergic imbalance in these structures [68, 69].
Nguyen et al. [70] used in silico methods to clarify the genetics underlying the contribution of dopamine the etiology and pathogenesis of autism and found genes implicated that regulate both Ca++ metabolism and dopaminergic neurotransmission. They found proteins implicated in ASD regulate dopamine signaling in multiple places including reuptake and catabolism, and they defined discrete molecular clusters that act on systems implicit in dopaminergic systems such as androgen receptors that stimulate DOPA decarboxylase. Another finding was the potential role of dopamine mediating the modulation of dendritic spines which determine synaptic strength and may be important in the developmental delays associated with ASD [71].
In an interesting cybernetic model, Kriete and Noelle [72] developed a sophisticated methodology to investigate the role of dopamine and the changes in executive function associated with autism. They showed that the intensely focused cognition associated with autism, as well as the pathognomonic lack of cognitive plasticity and inability to react with appropriate conscious focus to changes in the stimulus milieu could be modeled as changes in dopaminergic systems in the prefrontal cortex. By differentiating cognitive control from plasticity, and further by showing how developmental changes in younger brains can account for the timing of the manifestation of autistic symptoms, these authors findings support a causal adrenergic mechanism underling at least some of the symptoms associated with autism.
Taken together, a good case can be made for dopamine as a key mediator of the motor, speech, social behavior, behavioral perseveration, and reward aberrations that are typical symptoms of autism. The precise regulation of dopaminergic function of autonomic function appears to involve the projection of Purkinje cells to the medial prefrontal cortex (mPFC) and the ventral tegmental area (VTA) of the striatum. Atrophied Purkinje cells is one of the most consistent neuropathologies associated with autism [73, 74, 75, 76], and MRI data indicates persons with autisticism have smaller than normal cerebellar vermal volume [77]. Mice with diminished Purkinje cell mass evidence numerous autistic symptoms such as repetitive behaviors and impaired executive function [78]. Cerebellar Purkinje cells project to the mPFC where it appears they modulate dopaminergic transmission in this region directly, and via a remodeling of the VMA and thalamic interactions with the mPFC, and it has been suggested that cerebellar deficits observed in autism result in cortical, thalamic, and striatal integration via dopamine mediated pathways. [79].
An immunologic linkage of dopaminergic function in autism was reported by Kirsten et al. [80] when they prenatally exposed rat pups to lipopolysaccharide, a stimulator of innate and adaptive immunity. Autistic symptoms of impaired communication, deficits in learning and memory, and repetitive/restricted behavior were observed in the presence of impaired tyrosine hydroxylase (TH) function which was taken as a marker of reduced striatal dopaminergic function. Support for this concept was also found when rat pups were given poly I:C, an immunogenic stimulator, and upregulation of various genes associated with dopamine neural development were observed [81].
The phosphatase and tensin homolog on chromosome ten (PTEN) is tumor inhibitory gene that inhibits PI3K and MAPK pathways, and a germline mutation of this gene has been associated with autism [82]. Mouse mutations of this gene have resulted in symptoms similar to autism [83], and PTEN deletions have been found to enhance the survival and the function of dopaminergic neurons [84]. Work in this area has shown that mice with PTEN mutations have elevated TH and DA2 receptors in the striatum and prefrontal cortex, that PTEN reduces TH phosphorylation via MAPK suppression, downregulates dopamine synthesis in PC12 (pheochromocytoma) cell cultures, and that a PTEN-TH pathway may function as a “core regulator of dopamine signaling”. Moreover, this mechanism appears to be operative in autistic patients, as 3 PTEN mutants identified in autistic patients cannot suppress TH, which supports the concept of TH suppression as a potential mechanism for therapeutic intervention in autism [85].
Consistent with the finding that TH over activity might underlie the symptoms of autism is the finding by D’Souza et al. [86] that the commonly used model for autism in which symptoms in animals are induced by administering valproic acid is related to the ability of this agent to induce TH transcription at every concentration tested.
Autism is associated with gastrointestinal pathology from the esophagus to the colon [87, 88, 89, 90, 91]. The literature suggests that GI pathophysiology is an intrinsic component of autism in many patients and may be a central component to the etiology of the disease. GI problems have been reported in 42% of children with ASD and 12% of controls, with chronic diarrhea and constipation being the most prevalent problems. The severity of these problems correlates with the severity of ASD [92]. It is noteworthy that in both GI dysfunction and ASD imaging reveals abnormalities in brain regions associated with emotional and sensory functions [93, 94], and GI problems contribute to behavioral problems, attentional deficits, and self injury [95]. Gut bacteria influence intestinal permeability, mucosal immunity, the enteric nervous system, pituitary functions, and the modulation of pain (cited [96]).
There is increasing reason to believe that the interaction between gastric microbiota and the brain are contributory to the symptoms seen in ASD. This is mediated via the autonomic innervation of the intestine and the hypothalamic–pituitary axis which is innervated by catecholamines and which generates GI signaling molecules affecting enteroendocrine and mucosal immune cells. The “Gut Brain Axis” is comprised of central and peripheral nervous systems as well as the neuroendocrine and immune systems, and communication is bidirectional, with vagal inputs to the brain as well as endocrine and neuroendocrine signaling [97]. Catecholamines are associated with stress reactions and, interestingly, GI microbiota respond to stress with changes in their efferent and afferent catecholamine responses (reviewed in [98]).
A trial of 36 autistic children found pain, chronic diarrhea, bloating, GI irritability, chronic gastritis, esophagitis, chronic duodenitis, diminished carbohydrate digestive enzymes and reduced pancreatic exocrine secretion in response to secretin challenge [88]. Secretin has not been found to be an effective treatment for autism. In a survey of parents of 500 autistic children, half responded that their children had loose stools or chronic diarrhea, and intolerance for wheat and cow’s milk [99]. A number of reports mention improvements in autistic symptoms when reduced gluten and casein diets are implemented and the return of symptoms when these diets are terminated (cited in [100]).
Lucarelli et al. [101] observed an improvement in social skills and the ability to communicate in a trial of 36 autistics who were given diets with diminished gluten and/or cow’s milk, with improvements observed in 5 of 7 objective behavioral scales. Similar findings have been reported by others [102, 103, 104, 105]. Following one year on this diet symptoms returned upon termination of the dietary restrictions [104]. Intestinal permeability was found increased to lactose in a number of high functioning autistic children compared to age matched controls, with no increased permeability to mannitol, which was interpreted to mean a diminution in the tight junctions of gut epithelium [106] and the subsequent release of incomplete gluten and casein digestive products. Autistic patents reportedly manifest significantly higher levels of IgA for casein, gluten, lactalbumin and β-lactoglobulin [101, 107].
These observations give rise to the Leaky Gut Hypothesis of Autism, which states that various digestion products can enter the blood through leaky tight junctions in the gut and interact with the immune and central nervous systems in ways that facilitate the onset of autism. Gut peptidases release short chain peptides called exorphins that have structural similarity to endorphins. Gliadomorphins and casomorphins are stable examples of these peptides that are known to induce psychosis [108]. β-Casomorphin-7 is elevated in the urine of autistic patients [104], and when in infused into the blood stream of rats has been shown to activate the transcription of the gene
While controversial, elevated short chain fatty acids (SCFA) have been associated with autism [110], and both central and peripheral administration of propionic acid (PPA) to rats induces ASD-like impairments that include aberrant motor movements, stereotyped repetition, EEG changes, cognitive deficits, perseveration and social impairment, as well as increased oxidative stress, glutathione depletion, neuro-inflammation, altered lipid profiles and more [111]. SCFA are digestive products derived from fiber and protein. The most common SCFA include propionic PPA and butyric acid (BA) [112]. BA and PPA are metabolized in the liver via the portal circulation, however areas of the distal colon are outside of the portal circulatory bed, and the systemic effects of BA and PPA are believed to be significantly underestimated [110, 112]. SCFA, including PPA, activate G protein coupled neural, effect neurotransmitter synthesis and release, and mediate such diverse events in the nervous system as Ca++ gating, mitochondrial function, lipid metabolism, immune function, gene expression and the role of tight junctions [110]. SCFA are believed to modify the activity of TH, and there are 3 ways in which the SCFA BA modifies TH activity: (1) modulation of transcription via chromaffin remodeling, (2) activation of various transcription mediators, and (3) by interfering with TH mRNA [113, 114, 115, 116]. Subsequent work by Nankova, et al. [117] have shown that PPA elevates TH mRNA levels and that SCFA increase TH and subsequent catecholamine synthesis.
This dietary model allows for the elevation of cortical and striatal dopamine activity via elevated TH synthesis and activation, and which has been invoked as a potential mechanism for the actions of risperidone [118, 119], one of the two drugs approved for the treatment of the irritability associated with autism. It is worth noting in this context that PPA is structurally similar to valproic acid (VA), and has similar effects to VA, which is a treatment known to induce autistic symptoms, and used as a model for this purpose [120, 121, 122]. As cited above, VA appears to induce ASD- like symptoms by stimulating TH transcription in a manner similar to butyrate [86].
It is worth noting that relative to the participation of gastrointestinal events which may underlie autism, recent developments in the study of the human biome and investigations into GI function have revealed that the gut is the source of a number of neurotransmitters and neurotrophic factors, thus opening a previously understudied source of pharmacologic agents which may regulate CNS function.
In the work discussed above, it is important to note that PPA activates peroxisome proliferator-activated receptor gamma (PPAR-γ), and that this orphan receptor has been shown to have independent effects on the mediation of catecholamine and opioid pathways by SCFA [128], and that, as discussed below, PPAR is considered to be a “master regulator” of lipid homeostasis both centrally and peripherally. This later finding plays into the growing literature of lipid metabolism dysregulation in autism. PPAR also has immunologic functions that have been found to be related to metabolic and neurologic pathologies [129].
Any comprehensive approach to the treatment of autism must accommodate many different organ systems, certainly the gut and the CNS. As discussed above, the neurotransmitter function of dopamine is well known, including its modulatory effects on motor function, mood, emotion, irritability, reward, and other systems which are affected by autism. However, there also exists in the mesentery a paracrine dopaminergic system that regulates the secretion of bicarbonate [130], the secretion of digestive enzymes by the exocrine pancreas [131], and which controls sodium transport in the lower intestine [132]. Dopamine also has documented effects on gut motility and mucosal blood flow [133, 134, 135]. As early as 1994 elevated blood levels of levels of dopamine have been associated with autism [136]. It is known that ASD is associated with elevated levels of dopamine in the tracts linking the amygdala and prefrontal cortex in children with ASD [137, 138].
What is less known is that approximately 42–46% of the dopamine in the body is produced in the gut. Eisenhower and colleagues at NIH [139] studied 8 patients undergoing elective abdominal surgery and 47 patients who underwent cardiac catheterization. Tissue samples from the stomach and duodenum were obtained and compared, as were arteriovenous concentration differences and rates of renal clearance of dopamine and its metabolites in conditions of different sympathetic nervous backgrounds for dopamine not converted to norepinephrine. They found considerable dopamine synthesis in the stomach, pancreas, and duodenum, with renal elimination of dopamine and its metabolites. Dopamine has a naturetic function in the kidney; however, there was significant overflow of dopamine into the renal venous circulation that allows for systemic effects. As expected, cells in the stomach, pancreas, and duodenum stained positive for TH. The authors could not account for the amount of dopamine added to the mesenteric venous circulation, as it cannot be explained by sympathetic activity or diet, and their results were consistent with findings in swine [140].
In keeping with the concepts presented herein, it is relevant that in the liver, bile salt production and release are also under the control of dopamine [141, 142]. Bile salts are known to occur not only in the periphery, but in the CNS as well, where they appear to contribute to neurologic decline and blood brain barrier permeability [143, 144]. Bile acids are the predominant steroid in the brain, with levels that are 10x greater than those found in the blood indicating local synthesis, and with higher titers than that of pregnanolone, which was once considered the predominant neurosteroid [145].
In the brain, it has been observed that chenoxydecholic acid or deoxycholic acid induce the phosphorylation of occludin and increase the permeability of tight junctions via an Rac-1 dependent mechanism [146], making it conceivable that tight junctions in the gut are similarly effected by bile salts under the control of dopamine. It is well known that bile salts upregulate the orphan X receptors Farnesoid X Receptor (FXR), Liver X Receptor (LXR), Retinoid X Receptor (RXR) and PPAR. These nuclear receptors regulate the metabolism and homeostasis of glucose and lipids in numerous ways, including the transcription of the genes that regulate energy metabolism. Beyond the role of lipids in cell membranes and myelin sheaths, there is a growing body of literature to support the concept that lipids play a crucial signaling and regulatory role in cognition and other CNS events. This would appear to be significant as the brain comprised fundamentally of lipid and has the highest rate of glucose utilization in the body.
While it is commonly stated that autism occurs more frequently in males, at a rate of 4 boys for each girl [147], it is less commonly known that in severe autism this ratio increases to 11 to 1 [148]. Numerous sexual dimorphisms in the brain have been described (reviewed in [149]), such as brain size, hemispheric communications, differential gene expression, and more. It is worth noting that there is a growing body of literature implicating dopamine modulation of behavior as part of these sexual dimorphisms. One mechanism which may underlie the sexual dimorphism seen in the expression of ASD may relate to
Consistent with the increased prevalence of ASD in males, work in a mouse model has shown that a 16p11.2 gene deletion, which is associated with autism, affects the striatal reward system. While both sexes had 50% reductions in mRNA associated with ERK1, an important signaling kinase, in males there was an increase in ERK1 activation at baseline and in response to sugar in a manner associated with reduced striatal plasticity not shown in females. These changes were associated with an overexpression of dopamine D2 receptors in the striatum [150].
A mechanism by which sleep disturbances associated with ASD may be mediated involves the striatum, an area known to coordinate reward, learning and cognitive behaviors [151, 152] as well as to modulate circadian locomotor and retinal responses [153, 154]. This locus has been shown to be responsible for the maintenance of normal circadian rhythm functionality, and this system appears to be controlled by dopamine. Activation of D2 receptors has been found to regulate clock genes in the striatum, controlling circadian events. Hood et al. [155] found that depletion of striatal dopamine by various methods, including the use of AMPT, blunts normal circadian functions and that daily dopaminergic activation is required to maintain normal circadian rhythmicity.
In the context of a dopamine mediated model of autism, it is interesting to note that bile acids under catecholamine control inhibit the GABAA receptor [156, 157] in a manner that that diminished GABA related inhibitory post synaptic potentials. Inhibition was observed to occur in a stereospecific receptor-ligated, ion channel dependent manner, independent of lipophilicity, and consistent with the behavior of other known GABA receptor blockers. Interestingly, the inhibitory potencies of various bile salts corresponded best with their binding constants with albumin.
Taken together there is evidence for a dopaminergic system which might underlay and unite the symptoms of autism which manifest as central nervous system changes in mood, attention, cognition, socialization, etc., and those seen in the gut as changes in secretory, digestive and excretory functions.
ASD and energy metabolism are associated in several ways beyond the gut with glucose and lipid metabolism affected. Key among them is the role of bile salts under the control of catecholamines. Bile regulates FXR, LXR, and PPAR which are involved in the regulation of glucose metabolism, insulin sensitivity, lipid signaling and homeostasis. As a class, these ligand-inducible receptors are upregulated in the presence of their ligand, such as bile salts, and after binding they migrate to the nucleus where they exert genomic and epigenomic effects upon transcription and translation of the genes that mediate glucose and lipid utilization (for reviews see: [158, 159, 160, 161, 162, 163, 164, 165]).
Diabetes and metabolic syndrome are recognized comorbidities of ASD [154]. Catecholamines regulate bile acid release and the FXR upregulates the synthesis and secretion of bile salts from the gall bladder by stimulating the bile salt efflux pump in order to provide bile to solubilize fat soluble nutrients and vitamins from the gut and may have a similarly stimulate FXR in the brain. In mice, FXR deficiency leads to insulin resistance and reduced glucose tolerance [163, 166, 167], and the finding of FXR in pancreatic islet cells that affects insulin release allows for a regulatory role of local bile acid concentrations in insulin release and glucose tolerance [168, 169]. In the CNS, it is commonly known that the influence glucose receptors in the hypothalamus, carotid bodies, and other sites summate to mediate the central nervous control of glucose metabolism. Eating, satiety and similar energy mediated events in the brain are known to be modulated by the sympathetic nervous system, predominantly by dopaminergic systems [170]. Sympathetic afferents from the hypothalamus and other central site, under the control of various agents such as catecholamines and leptin are known to regulate glucose synthesis, insulin sensitivity and similar events (reviewed in [171, 172, 173, 174]). Severing the autonomic projections to the islets of Langerhans resulted in a 75–90% impairment in the ability to regulate serum glucose in response to insulin induced hypoglycemia [175]. Although the effects of catecholamines on lipid homeostasis have been defined in the gut, these mechanism can also serve as a model in brain tissue, since this organ contains 25% of the body’s cholesterol but only 2% of its mass [176], and most of the lipid synthesis and metabolism in the brain occurs
There exists a growing body of work that lipid metabolism underlies cognitive function. Accumulating evidence supports the idea that HDL and the mechanisms that regulate lipid metabolism also influence neurodegenerative diseases including autism, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, and others [177]. Just as HDL have a demonstrably cardio-protective role, they also appear to have a neuro-protective role. HDL are made throughout the body and serve to remove excess cholesterol from peripheral tissues for excretion in the bile and for steroidogenesis. In a study of 139 centenarians it was found that plasma HDL correlated with mental acuity in age [178]. This was confirmed in another study of 159 centenarians [179], again in a longitudinal population study in Amsterdam [180], and supported by the finding that low HDL was associated with intellectual impairment in age [181, 182, 183]. Effectors like cholesteryl ester transfer protein (CETP), which increase HDL are similarly associated with durable cognitive function in later age [179, 184, 185].
Bile salts can be released inappropriately via a “leaky gut” syndrome that ASD or they can be made locally in the brain under the control of catecholamines. Their synthesis and biologic functions have been described in a variety of non-gastric tissues, including the brain. As reviewed by Quinn and DE Marrow [186], bile acids and their salts are now viewed as steroid hormones, and not merely as detergents that solubilize lipids. Consistent with their role as the predominant brain steroid [145], in the rat that the primary bile acid chenoxydecholic acid composed 95% of brains bile acid. Further, the most abundant oxysterols found in the CNS are the C22 and C26 intermediates of bile acid synthesis.
One of the agents that regulates HDL homeostasis is the LXR, which is upregulated in the presence of the bile salts that solubilize and accompany plasma and tissue lipids. LXR is a cholesterol sensing and regulating molecule and cholesterol functionality is necessary for heathy cell membrane function, which is crucial to synaptic function. LXR has been demonstrated to improve cognitive performance in animal models of Alzheimer’s disease presumably via the induction of HDL [cited: [177]].
Once believed to be the master regulator of glucose and lipid metabolism, PPAR-γ is associated with the maturation and development of adipocytes, the deposition of lipids, glucose metabolism, insulin sensitivity and other related events [187]. PPAR-γ has been shown to be mediated by bile salts and dopamine via phospholipase C in a calcium dependent manner, with elevations in dopamine resulting in increased PPAR-γ in cardiac myocytes [188]. PPAR-α is abundantly expressed in skeletal muscle, liver and brain [189, 190], and is associated with dyslipidemia, a condition often seen in autistic patients [190, 191, 192, 193]. PPAR-α has been associated in the literature with central dopaminergic function as it appears to influence the activity of antipsychotic agents known to interact with dopaminergic neurologic systems [194, 195]. It has also been implicated in reduced GABAergic interneuron firing in pyramidal neurons resulting in cortical excitation [196, 197, 198, 199]. D’Agastino et al. [200] have shown that central nervous system reduction in this “Master Regulator of Lipid Homeostasis” is associated with autistic like behaviors that include; repetitive and perseverative behaviors, loss of cognitive flexibility and reduced spatial information processing. They documented PPAR-α deprivation resulted in resistance to central glutamate stimulation via NMDA receptors, reduced GABAergic interneurons in the frontal cortex and hippocampus with dystrophic neurons in these structures, and increased gamma waves with decreased theta wave frequency.
Historically, there is a well-defined relationship between stress, catecholamines, and plasma lipids (reviewed in [25]). Stress, which is characterized by elevated levels of circulating catecholamines, is associated with increased plasma lipids, reduced glycemic control, diminished insulin secretion and insulin insensitivity, all of which can be associated with ASD. This is consistent with the aggressive fighting responses associated with catecholamines significantly elevating NGF in sympathetic ganglia and in the absence of ACTH or corticoids [201]. Various central mechanisms have been implicated in these events, including, the ventromedial nucleus of the hypothalamus and hippocampal efferents to the hypothalamus. These central nervous system events can be translated into hyperlipidemia in three ways: via adrenal epinephrine release, via elevated pancreatic glucagon secretion, and via the regulation of hepatic glycolysis and gluconeogenesis. All three of these pathways are regulated by the sympathetic nervous system.
These findings fit with an emerging metabolic model of autism in which CNS control of energy metabolism and the autonomic nervous system as an integrating modality that senses and regulates those changes in the periphery and modifies these effects centrally. Integration of reward, satiety, insulin release and sensitivity, related endocrine events, as well as circadian clock mechanisms and similar systems which are impaired in autism appear to be mediated largely in the hypothalamus and brain stem via various nutrient sensing mechanisms which reticulate throughout the CNS to the cortex, basal ganglia, pyramids and so forth. (for a review see [202]). Cholesterol, LXR, PPARs and other agents which are known to regulate energy metabolism in the periphery appear to do so in the CNS as well and these mechanisms map well to the deficiencies seen in autism. It is particularly noteworthy that many of the events mediated by the nuclear receptors LXR and PPAR are cell and ligand specific, and that changes in cholesterol metabolism can have profound changes on membranes and their functions. That these changes can vary as a function of cell type provides a mechanism by which metabolic impairments in discrete brain regions may occur in ways that compromise specific nuclei and tracts.
Taken together, there appears to be linkage between catecholamine metabolism both centrally and peripherally, the regulation of energy homeostasis, and central nervous system function in a variety of pathologic states. There is a growing body of evidence to indicate a relationship between central and peripheral nervous system regulation of glucose and energy homeostasis, and abnormal cognitive function, as exemplified in autism.
Nerve growth factor (NGF) in the brain is stimulated by catecholamine synthesis [203] and regulates the morphology of the catecholamine synapse. Neurotropic NGF is required for catecholaminergic neuron survival and differentiation. It is released into the synapse with catecholamines and it determines the synaptic architecture with elevated levels of NGF resulting in elevated levels of TH, catecholamine synthesis and synaptic neurotransmission [204, 205, 206] since NGF concentrations have a direct effect on the budding and arborization of catecholamine dendrites [207, 208] as well as the density of target tissue innervation [209, 210] Similarly, elevated catecholaminergic transmission is associated in a dose dependent manner with brain derived nerve growth factor (BDNF) in a pre-synaptic manner [211]. This is consistent with the finding that the loss of a Brain Derived Nerve Growth Factor (BDNF) allele in a mouse knockout model.prevented the loss of sympathetic islet innervation in an immune based diabetic model [212].
NGF has a hyperplastic, hypertrophic effect on catecholaminergic neurons characterized by elevated TH [213, 214, 215] that results from binding to its tyrosine kinase receptor TrkA expressed on the axons of catecholaminergic neurons [216]. In this way pre-synaptic release of neurotransmitters exerts a differentiating effect post-synaptically to mediate catecholamine synaptic architecture, the number of neurons, and innervation density [207, 217].
NGF is known to increase with increased catecholaminergic nerve traffic and with stress [218], and results in the sprouting of new nerve fibers in the stellate ganglion and elsewhere in the sympathetic nervous system [219, 220]. NGF and BDNF are important mediators of neurologic function in the brain with the ability to mediate short and long term neurologic function in areas associated with ASD like the cortex and hippocampus [221, 222]. NGF has been shown to promote sympathetic neural growth, differentiation and to enhance target innervation [205, 208, 209, 210, 223, 224] and NGF is known to be elevated in PTSD [225, 226, 227], a disease with a similar constellation of symptoms to autism. NGF leads to sympathetic sprouting and supports dendritic geometry of the newly sprouted nerve terminals for the life of the sympathetic neural substrate [228, 229]. NGF is known to effect memory directly [230], indirectly [220, 231, 232], and through its actions on NE, as well as indirectly via hypothalamically mediated release of cortisol [233].
LI:79 is D,L α-methyl-para-tyrosine, abbreviated AMPT. It inhibits the activity of TH, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA) which is the rate limiting step in catecholamine synthesis. L α-methyl-para-tyrosine was approved by the FDA in 1979, is marketed under the name Demser®, and is typically called metyrosine and abbreviated AMT.
α-methyl-para-tyrosine is a tyrosine analog that competes competitively for TH and is excreted mostly unchanged in the urine. Demser was approved for presurgical use in the treatment of pheochromocytoma, a catecholamine producing tumor which when manipulated surgically releases pathologic levels of catecholamines into the circulation that can result in serious AE. Demser minimizes this potentially serious complication and can treat pheochromocytoma patients who were not qualified for surgery. It is approved for use in doses between 1 and 4 g/day in divided doses. The doses of L1-79 used in autism clinical trials was 90 mg tid to 400 mg tid of which only 50% is the L-isomer.
While Demser is intended to deplete adrenal medullary catecholamines as fully as possible L1-79 is intended to reduce catecholaminergic tone slightly, a use for which Demser is inappropriate. The published half-life for Demser is 3.53 hours [234], whereas the half-life for L1-79 has been found to be between 10.3–14.3 hours [235]. This is presumed to result from a competitive inhibition between the dextro and levo forms of the molecule for the L-amino acid transport mechanisms in the body resulting in more time on target for the racemate. Since only 50% of L1-79 is the active L-isomer, and as it persists at the receptor for a longer duration, L1-79 is suitable for bid dosing and is much better tolerated at the lower doses used to get a therapeutic effect in ASD.
Adverse events associated with Demser include sedation that typically habituates but might persist at doses >2 g/d, temporary changes in sleep, extrapyramidal signs including tremor at high doses, trismus and parkinsonism at high doses, dose dependent confusion that resolves with dose reduction, dose related diarrhea, and infrequent AE that include crystalluria, nausea and vomiting, and impotence. None of these have been observed in autism except for 2 patients who manifest crystalluria without clinical consequence at the 200 mg tid dose.
It should be noted that D,L α-methyl-para-tyrosine as described herein for the treatment of autism is also used in a polytherapeutic regimen for the treatment of patients with late stage cancer (SM-88) under the Tyme Technologies Inc. at doses that are a fraction of the lowest approved dose for Demser, and has been well tolerated.
In a proof of concept trial in 8 patients of both sexes between the ages of 2.75 to 24 years of age and without Rett or Fragile X syndrome. Doses began at doses of 90 mg tid and were escalated to 200 mg tid for most patients with two patients receiving a brief course at 400 mg tid, which was not found to increase efficacy. All doses were well tolerated. Patients were washed out of their legacy medications and 6 patients were maintained on L1-79 alone. Two patients were restarted on one of their legacy medications at lower than their pre-study dose. L1-79 in this study had a therapeutic effect on the core symptoms of autism as defined by the ABC-C (Figure 1), the CPRS (Figure 2), ADOS (Figure 3), and the CGI (Figure 4). This includes improvements in socialization, communication, repetitive movements, sleep disturbances, and other symptoms of ASD. Interestingly, the Autism Diagnostic Observation Schedule 2 (ADOS), which is the “gold standard” for quantifying the lifetime severity of ASD was profoundly influenced by L1-79 treatment. In the 6 patients in whom the ADOS was measured a mean decrease of 30% was observed with one patient experiencing a reduction of 47% (Figure 3) which took him below the threshold for a diagnosis of autism following 10 weeks of treatment, although he was still on the spectrum [236]. As can be seen in the ABC-C scores, these effects were observed rapidly.
Proof of concept study: Aberrant behavior checklist-community (ABC-C) scores. Domain scores for each participant during weeks 1 to 8. Because of participant-specific factors, ABC-C scores were not recorded at all visits for all participants.
Proof of concept study: Connor parent rating scale (CPRS) at 4-week intervals for 8 participants. Some participants did not have all assessments.
Proof of concept study: Autism diagnostic observation schedule (ADOS) scores for the 6 participants tested at baseline and week 10.
Proof of concept study: Clinical global impressions (CGI) scores for 8 participants. Top panel shows absolute scores at week 1 and week 8. Bottom panel shows the change from week 1 to week 8. The qualitative interpretation at week 1 appears above each participant change in score, and the interpretation at week 8 is shown below each bar. Each participants efficacy index at week at appears at the bottom.
A follow-up randomized, double blind, placebo-controlled 28-day study of 39 patients has been completed and the results are currently in preparation for publication [237]. While 28 days was too short to demonstrate much of an effect, per the FDA the existing toxicology did not permit a longer treatment duration at that time. Participants were male patients between the ages of 13 and 21 years of age with a diagnosis of ASD based on DSM-5 criteria and confirmed by Autistic Diagnosis Interview-Revised (ADI-R), ADOS and expert clinical opinion, stable on no more than one concomitant medication with no planned changes in psychosocial interventions during the study and sufficiently tolerant and capable of complying with the requirements for this study. Results from this brief study can be seen for the CGI (Figure 5), Social Response Scale-2 (SRS) social motivation T scores (Figure 6), ADOS (Figure 7), Vinland Adaptive Behavior Scale-II (VABS) socialization standard score (Figure 8), and the SRS DSM-SCI T scores (Figure 9).
Pilot study: Change in clinical global impression-severity (CGI-S) over time and individual patient responses from baseline to week 4. Upper panel is the change over time by study week for L1-79 200 mg and placebo. The lower panel is individual patient responses for L1-79 200 mg and placebo.
Change from baseline over time and individual patient responses in the social responsiveness Scale-2 (SRS-2) social motivation T-score at week 4. Upper panel is change from baseline over time for L1-79 200 mg and placebo. Lower panel is individual changes for L1-79 200 mg and placebo.
Pilot study: ADOS score changes for 200 mg dose and placebo after 28 days of treatment. Negative scores represent improvement.
Upper panel: Change from baseline over time and individual patient responses Vineland adaptive behavior-II (VABS) socialization standard score at week 4 for L1-79 200 mg and placebo. Lower panel individual changes for L1-79 200 mg and placebo.
Pilot study: Upper panel is the change from baseline over time in the social responses scale – 2 DSM-SCI for week 4 L1-79 200 mg and placebo. Lower panel individual changes for L1-79 200 mg and placebo.
Anecdotally, numerous salutary behaviors were observed in these studies. Two teenage boys hugged and kissed their parents for the first time. One teenager with a history of self mutilating behavior stopped hurting himself. Subjective aspects of socialization such as empathy, effective communication, emotional expression, better sleep patterns, and engagement with peers were reported by parents and teachers and a school bus driver who were unaware of the trials.
The proof of concept study was conducted under the assumption that, per the 505(b)(2) guidelines, any stereoisomer of a drug is considered to be the same drug, and therefore the use of L1-79 was an unapproved use of an approved agent (Demser). In subsequent discussions with the FDA this was disallowed. The FDA required that the proof of concept study be discontinued and approved a follow-on pilot study that was limited to 28 days based upon the toxicology then in existence. It is noteworthy that when study drug was discontinued after the 28-day pilot study patients regressed to baseline within one week whereas the proof of concept patients who had been on study drug for as long as 6 months maintained some residual benefit following the discontinuation of medication.
We hypothesize that the mechanism begins with some process that stimulates massive levels of sympathetic neural traffic that gives rise to high levels of catecholamine synthesis and release which is associated with high levels of both BDNF and NGF [238]. NGF receptors are found on sympathetic nerves [239] and are responsible for maintaining catecholaminergic synaptic architecture due to their control on the budding and arborization of catecholamine dendrites [207, 208] and density of innervation [209, 210].
Elevated levels of synaptic nerve growth factors associated with catecholamine release may result from a variety of factors including genetics, cognitive or biological stress such as exposure to pesticides, fever in utero, complications of pregnancy, or other causes. This catecholamine elevation results in elevated levels of nerve traffic due to growth factor induced budding and arborization of catecholamine nerve terminals and collaterals. As these growth factors are required to support the dendritic architecture of the neurons over their life, this elevated level of NGF & BDNF become chronic, resulting in an enhanced level of synaptic morphology and a consequent elevation of catecholamine release from these new hypertrophic synapses. This change in the level of catecholaminergic tone and the elevated release of catecholamines creates a persistent imbalance in the CNS and between the sympathetic and parasympathetic arms of the autonomic nervous system resulting in an overstimulation of some tracts and depletion in others. This imbalance caused by the growth factors centrally and peripherally results in both neurologic and metabolic pathology.
Because this involves catecholaminergic mechanisms in the brain, gut, mesentery, and elsewhere in the body, changes in emotional expression, speech, cognition, memory, circadian rhythms, gut function, energy metabolism, and the entire panoply of autism related symptoms can potentially be ascribed to aberrant catecholaminergic function. It is worth noting that NGF exerts presynaptic functionality with both pre- and post-synaptic effects with both short- and long-term effects on catecholaminergic neurotransmission [216]. Thus, the effects of L1-79 are not mimicked by receptor blocking agents which only reduce post-synaptic depolarization but do nothing to address the underlying abnormality of excessive catecholaminergic collaterals and a hypertrophic dendritic architecture induced and maintained by growth factors.
Since NGF is known to stimulate TH [215, 240, 241, 242] and L1-79 inhibits TH, and given both the short and long term effects of NGF exposure on sympathetic substrates, L1-79 is likely to have a therapeutic effect in the short and intermediate term of treatment of autism and may even have a disease modifying effect in the long run if the hypertrophic synaptic architecture regresses to a more homeostatic morphology. That is, if the underlying pathology of ASD is due in whole or part due to elevated catecholaminergic tone due to the release of growth factors associated with catecholamine release, then by reducing catecholamine synthesis, storage and release along with the associated release of NGF and BDNF a reduction of symptoms is likely to result. If, over a longer period, the reduction of NGF and BDNF enables a restoration of normal synaptic morphology then a persistent reduction of ASD symptoms may be possible, even in the absence of treatment.
L1-79 inhibits the rate limiting step in the synthesis of catecholamine, including dopamine and norepinephrine. Unlike the L-isomer of AMPT (Demser), L1-79 has a better kinetic profile for the use of L1-79 as a treatment for ASD. It’s presynaptic mechanism of action likely results in a diminution of both catecholamines and related growth factors which we hypothesize will reduce symptoms of ASD in a manner not possible with receptor blockers, and which with long term use may reduce the hypertrophic architecture of catecholamine synapses in ASD back to a homeostatic morphology. An exaggerated catecholaminergic mechanism underlying ASD and its associated comorbidities can explain a variety of potential influences on the disease including the effects of bile, orphan receptors, lipids, glucose and other factors.
Preliminary results observed following the administration of L1-79 to autistic juveniles and adolescents has resulted in consistent improvement in the core symptoms of in two early studies [214, 215] not seen with previous agents.
L1-79 appears to be an effective therapy for the treatment of autism in children empirically with a novel mechanism of action that is supported by the scientific literature.
The author wishes to acknowledge the inventorship and collegiality of Steve Hoffman.
Dr. Rothman is the managing director of Yamo Pharmaceuticals.
In our mission to support the dissemination of knowledge, we travel throughout the world to present our publications, support our Authors and Academic Editors at international symposia, conferences, and workshops, as well as to attend business meetings with science, academic and publishing professionals. We are always happy to meet our contributors in our offices to discuss further collaborations. Take a look at where we’ve been, who we’ve met and where we’re going.
",metaTitle:"IntechOpen events",metaDescription:"In our mission to support the dissemination of knowledge, we travel worldwide to present our publications, authors and editors at international symposia, conferences, and workshops, as well as attend business meetings with science, academia and publishing professionals. We are always happy to host our scientists in our office to discuss further collaborations. Take a look at where we’ve been, who we’ve met and where we’re going.",metaKeywords:null,canonicalURL:"/page/events",contentRaw:'[{"type":"htmlEditorComponent","content":"16-18 June 2020 Smart University Forum #SUF20, Ankara, Turkey
\\n\\n19 December 2019 IntechOpen and Enago webinar: A Guide to Academic Book Writing and Publishing
\\n\\n27-28 November 2019 14th Munin Conference on Scholarly Publishing, UiT The Arctic University of Norway, Tromsø campus
\\n\\n23 October 2019 Break on Through to the Open Side - Global Online Panel Discussion
\\n\\n21 October 2019 SUFTalks - Istanbul, Sheraton Istanbul Ataköy Hotel, Istanbul, Turkey
\\n\\n21-27 October 2019 OPEN ACCESS WEEK
\\n\\n16-20 October 2019 Frankfurt Book Fair
\\n\\n10 October 2019 IntechOpen - Knowledge Unlatched Lecture & Drinks, The Shard, London, United Kingdom
\\n\\n16-18 September, 2019 Open Science Fair Porto, Portugal
\\n\\n12 September, 2019 ALPSP Annual Conference and Awards, De Vere Beaumont Estate, Old Windsor, United Kingdom. Panel: New Horizons in Open Research: Innovation in open books
\\n\\n27-28 August, 2019 Smart University Foundation, Ankara, Turkey
\\n\\n18-19 July, 2019 Spanish Research Council Meeting, Madrid, Spain
\\n\\n12 July, 2019 Lectures, Kings College London Waterloo Campus, United Kingdom Lecture. 1: Intro to Robotics (focus on robotics in the area of health) Lecture. 2: My career in publishing, my background, scientific open access publication and IntechOpen
\\n\\n24 June, 2019 Atypon Conference, Munich. The Future of Books
\\n\\n20-22 May, 2019 IntechOpen attends series of talks “Pint of Science Festival”, Bilbao. Glass and Txakoli, Nanoscience and Nanotechnology, Autonomous Cars
\\n\\n7 March, 2019 Humans in Space Lecture Series, Shard London
\\n\\n13 September, 2018 Peer Review Week, King’s College London
\\n\\n1-5 October, 2018 IROS Conference, Madrid. Legal issues, Cybersecurity and Policy in AI robotics, Interview with Prof. George Dekoulis
\\n\\n24-26 April, 2018 STM US 2018
\\n\\n19-23 March, 2018 Immuno Oncology Summit
\\n\\n19 March, 2018 Earth dynamics and the development of plate tectonics scientific meeting
\\n\\n15 March, 2018 5th symposium on molecular pathology in oncology – Hot Topics
\\n\\n13-14 March, 2018 WIRED Health
\\n"}]'},components:[{type:"htmlEditorComponent",content:'16-18 June 2020 Smart University Forum #SUF20, Ankara, Turkey
\n\n19 December 2019 IntechOpen and Enago webinar: A Guide to Academic Book Writing and Publishing
\n\n27-28 November 2019 14th Munin Conference on Scholarly Publishing, UiT The Arctic University of Norway, Tromsø campus
\n\n23 October 2019 Break on Through to the Open Side - Global Online Panel Discussion
\n\n21 October 2019 SUFTalks - Istanbul, Sheraton Istanbul Ataköy Hotel, Istanbul, Turkey
\n\n21-27 October 2019 OPEN ACCESS WEEK
\n\n16-20 October 2019 Frankfurt Book Fair
\n\n10 October 2019 IntechOpen - Knowledge Unlatched Lecture & Drinks, The Shard, London, United Kingdom
\n\n16-18 September, 2019 Open Science Fair Porto, Portugal
\n\n12 September, 2019 ALPSP Annual Conference and Awards, De Vere Beaumont Estate, Old Windsor, United Kingdom. Panel: New Horizons in Open Research: Innovation in open books
\n\n27-28 August, 2019 Smart University Foundation, Ankara, Turkey
\n\n18-19 July, 2019 Spanish Research Council Meeting, Madrid, Spain
\n\n12 July, 2019 Lectures, Kings College London Waterloo Campus, United Kingdom Lecture. 1: Intro to Robotics (focus on robotics in the area of health) Lecture. 2: My career in publishing, my background, scientific open access publication and IntechOpen
\n\n24 June, 2019 Atypon Conference, Munich. The Future of Books
\n\n20-22 May, 2019 IntechOpen attends series of talks “Pint of Science Festival”, Bilbao. Glass and Txakoli, Nanoscience and Nanotechnology, Autonomous Cars
\n\n7 March, 2019 Humans in Space Lecture Series, Shard London
\n\n13 September, 2018 Peer Review Week, King’s College London
\n\n1-5 October, 2018 IROS Conference, Madrid. Legal issues, Cybersecurity and Policy in AI robotics, Interview with Prof. George Dekoulis
\n\n24-26 April, 2018 STM US 2018
\n\n19-23 March, 2018 Immuno Oncology Summit
\n\n19 March, 2018 Earth dynamics and the development of plate tectonics scientific meeting
\n\n15 March, 2018 5th symposium on molecular pathology in oncology – Hot Topics
\n\n13-14 March, 2018 WIRED Health
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5817},{group:"region",caption:"Middle and South America",value:2,count:5282},{group:"region",caption:"Africa",value:3,count:1755},{group:"region",caption:"Asia",value:4,count:10511},{group:"region",caption:"Australia and Oceania",value:5,count:906},{group:"region",caption:"Europe",value:6,count:15915}],offset:12,limit:12,total:119159},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"0",sort:"ebgfFaeGuveeFgfcChcyvfu"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:27},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:9},{group:"topic",caption:"Business, Management and Economics",value:7,count:3},{group:"topic",caption:"Chemistry",value:8,count:11},{group:"topic",caption:"Computer and Information Science",value:9,count:9},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:9},{group:"topic",caption:"Engineering",value:11,count:24},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:7},{group:"topic",caption:"Mathematics",value:15,count:2},{group:"topic",caption:"Medicine",value:16,count:46},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:4},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:2},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9685",title:"Agroecosystems",subtitle:"Very Complex Environmental Systems",isOpenForSubmission:!1,hash:"c44f7b43a9f9610c243dc32300d37df6",slug:"agroecosystems-very-complex-environmental-systems",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/9685.jpg",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8564",title:"Cell Interaction",subtitle:"Molecular and Immunological Basis for Disease Management",isOpenForSubmission:!1,hash:"98d7f080d80524285f091e72a8e92a6d",slug:"cell-interaction-molecular-and-immunological-basis-for-disease-management",bookSignature:"Bhawana Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8564.jpg",editors:[{id:"315192",title:"Dr.",name:"Bhawana",middleName:null,surname:"Singh",slug:"bhawana-singh",fullName:"Bhawana Singh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9629",title:"Electroencephalography",subtitle:"From Basic Research to Clinical Applications",isOpenForSubmission:!1,hash:"8147834b6c6deeeec40f407c71ad60b4",slug:"electroencephalography-from-basic-research-to-clinical-applications",bookSignature:"Hideki Nakano",coverURL:"https://cdn.intechopen.com/books/images_new/9629.jpg",editors:[{id:"196461",title:"Prof.",name:"Hideki",middleName:null,surname:"Nakano",slug:"hideki-nakano",fullName:"Hideki Nakano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9161",title:"Frailty in the Elderly",subtitle:"Understanding and Managing Complexity",isOpenForSubmission:!1,hash:"a4f0f2fade8fb8ba35c405f5ad31a823",slug:"frailty-in-the-elderly-understanding-and-managing-complexity",bookSignature:"Sara Palermo",coverURL:"https://cdn.intechopen.com/books/images_new/9161.jpg",editors:[{id:"233998",title:"Ph.D.",name:"Sara",middleName:null,surname:"Palermo",slug:"sara-palermo",fullName:"Sara Palermo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8445",title:"Dam Engineering",subtitle:"Recent Advances in Design and Analysis",isOpenForSubmission:!1,hash:"a7e4d2ecbc65d78fa7582e0d2e143906",slug:"dam-engineering-recent-advances-in-design-and-analysis",bookSignature:"Zhongzhi Fu and Erich Bauer",coverURL:"https://cdn.intechopen.com/books/images_new/8445.jpg",editors:[{id:"249577",title:"Dr.",name:"Zhongzhi",middleName:null,surname:"Fu",slug:"zhongzhi-fu",fullName:"Zhongzhi Fu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8937",title:"Soil Moisture Importance",subtitle:null,isOpenForSubmission:!1,hash:"3951728ace7f135451d66b72e9908b47",slug:"soil-moisture-importance",bookSignature:"Ram Swaroop Meena and Rahul Datta",coverURL:"https://cdn.intechopen.com/books/images_new/8937.jpg",editors:[{id:"313528",title:"Associate Prof.",name:"Ram Swaroop",middleName:null,surname:"Meena",slug:"ram-swaroop-meena",fullName:"Ram Swaroop Meena"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7031",title:"Liver Pathology",subtitle:null,isOpenForSubmission:!1,hash:"631321b0565459ed0175917f1c8c727f",slug:"liver-pathology",bookSignature:"Vijay Gayam and Omer Engin",coverURL:"https://cdn.intechopen.com/books/images_new/7031.jpg",editors:[{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8158",title:"Veganism",subtitle:"a Fashion Trend or Food as a Medicine",isOpenForSubmission:!1,hash:"d8e51fc25a379e5b92a270addbb4351d",slug:"veganism-a-fashion-trend-or-food-as-a-medicine",bookSignature:"Miljana Z. Jovandaric",coverURL:"https://cdn.intechopen.com/books/images_new/8158.jpg",editors:[{id:"268043",title:"Dr.",name:"Miljana Z.",middleName:"Z",surname:"Jovandaric",slug:"miljana-z.-jovandaric",fullName:"Miljana Z. Jovandaric"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"2160",title:"MATLAB",subtitle:"A Fundamental Tool for Scientific Computing and Engineering Applications - Volume 1",isOpenForSubmission:!1,hash:"dd9c658341fbd264ed4f8d9e6aa8ca29",slug:"matlab-a-fundamental-tool-for-scientific-computing-and-engineering-applications-volume-1",bookSignature:"Vasilios N. Katsikis",coverURL:"https://cdn.intechopen.com/books/images_new/2160.jpg",editors:[{id:"12289",title:"Prof.",name:"Vasilios",middleName:"N.",surname:"Katsikis",slug:"vasilios-katsikis",fullName:"Vasilios Katsikis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5314},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9685",title:"Agroecosystems",subtitle:"Very Complex Environmental Systems",isOpenForSubmission:!1,hash:"c44f7b43a9f9610c243dc32300d37df6",slug:"agroecosystems-very-complex-environmental-systems",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/9685.jpg",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8564",title:"Cell Interaction",subtitle:"Molecular and Immunological Basis for Disease Management",isOpenForSubmission:!1,hash:"98d7f080d80524285f091e72a8e92a6d",slug:"cell-interaction-molecular-and-immunological-basis-for-disease-management",bookSignature:"Bhawana Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8564.jpg",editors:[{id:"315192",title:"Dr.",name:"Bhawana",middleName:null,surname:"Singh",slug:"bhawana-singh",fullName:"Bhawana Singh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9629",title:"Electroencephalography",subtitle:"From Basic Research to Clinical Applications",isOpenForSubmission:!1,hash:"8147834b6c6deeeec40f407c71ad60b4",slug:"electroencephalography-from-basic-research-to-clinical-applications",bookSignature:"Hideki Nakano",coverURL:"https://cdn.intechopen.com/books/images_new/9629.jpg",editors:[{id:"196461",title:"Prof.",name:"Hideki",middleName:null,surname:"Nakano",slug:"hideki-nakano",fullName:"Hideki Nakano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9161",title:"Frailty in the Elderly",subtitle:"Understanding and Managing Complexity",isOpenForSubmission:!1,hash:"a4f0f2fade8fb8ba35c405f5ad31a823",slug:"frailty-in-the-elderly-understanding-and-managing-complexity",bookSignature:"Sara Palermo",coverURL:"https://cdn.intechopen.com/books/images_new/9161.jpg",editors:[{id:"233998",title:"Ph.D.",name:"Sara",middleName:null,surname:"Palermo",slug:"sara-palermo",fullName:"Sara Palermo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8445",title:"Dam Engineering",subtitle:"Recent Advances in Design and Analysis",isOpenForSubmission:!1,hash:"a7e4d2ecbc65d78fa7582e0d2e143906",slug:"dam-engineering-recent-advances-in-design-and-analysis",bookSignature:"Zhongzhi Fu and Erich Bauer",coverURL:"https://cdn.intechopen.com/books/images_new/8445.jpg",editors:[{id:"249577",title:"Dr.",name:"Zhongzhi",middleName:null,surname:"Fu",slug:"zhongzhi-fu",fullName:"Zhongzhi Fu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8937",title:"Soil Moisture Importance",subtitle:null,isOpenForSubmission:!1,hash:"3951728ace7f135451d66b72e9908b47",slug:"soil-moisture-importance",bookSignature:"Ram Swaroop Meena and Rahul Datta",coverURL:"https://cdn.intechopen.com/books/images_new/8937.jpg",editors:[{id:"313528",title:"Associate Prof.",name:"Ram Swaroop",middleName:null,surname:"Meena",slug:"ram-swaroop-meena",fullName:"Ram Swaroop Meena"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7031",title:"Liver Pathology",subtitle:null,isOpenForSubmission:!1,hash:"631321b0565459ed0175917f1c8c727f",slug:"liver-pathology",bookSignature:"Vijay Gayam and Omer Engin",coverURL:"https://cdn.intechopen.com/books/images_new/7031.jpg",editors:[{id:"273100",title:"Dr.",name:"Vijay",middleName:null,surname:"Gayam",slug:"vijay-gayam",fullName:"Vijay Gayam"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8472",title:"Bioactive Compounds in Nutraceutical and Functional Food for Good Human Health",subtitle:null,isOpenForSubmission:!1,hash:"8855452919b8495810ef8e88641feb20",slug:"bioactive-compounds-in-nutraceutical-and-functional-food-for-good-human-health",bookSignature:"Kavita Sharma, Kanchan Mishra, Kula Kamal Senapati and Corina Danciu",coverURL:"https://cdn.intechopen.com/books/images_new/8472.jpg",editedByType:"Edited by",editors:[{id:"197731",title:"Dr.",name:"Kavita",middleName:null,surname:"Sharma",slug:"kavita-sharma",fullName:"Kavita Sharma"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8760",title:"Structure Topology and Symplectic Geometry",subtitle:null,isOpenForSubmission:!1,hash:"8974840985ec3652492c83e20233bf02",slug:"structure-topology-and-symplectic-geometry",bookSignature:"Kamal Shah and Min Lei",coverURL:"https://cdn.intechopen.com/books/images_new/8760.jpg",editedByType:"Edited by",editors:[{id:"231748",title:"Dr.",name:"Kamal",middleName:null,surname:"Shah",slug:"kamal-shah",fullName:"Kamal Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9536",title:"Education at the Intersection of Globalization and Technology",subtitle:null,isOpenForSubmission:!1,hash:"0cf6891060eb438d975d250e8b127ed6",slug:"education-at-the-intersection-of-globalization-and-technology",bookSignature:"Sharon Waller, Lee Waller, Vongai Mpofu and Mercy Kurebwa",coverURL:"https://cdn.intechopen.com/books/images_new/9536.jpg",editedByType:"Edited by",editors:[{id:"263302",title:"Dr.",name:"Sharon",middleName:null,surname:"Waller",slug:"sharon-waller",fullName:"Sharon Waller"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8564",title:"Cell Interaction",subtitle:"Molecular and Immunological Basis for Disease Management",isOpenForSubmission:!1,hash:"98d7f080d80524285f091e72a8e92a6d",slug:"cell-interaction-molecular-and-immunological-basis-for-disease-management",bookSignature:"Bhawana Singh",coverURL:"https://cdn.intechopen.com/books/images_new/8564.jpg",editedByType:"Edited by",editors:[{id:"315192",title:"Dr.",name:"Bhawana",middleName:null,surname:"Singh",slug:"bhawana-singh",fullName:"Bhawana Singh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9629",title:"Electroencephalography",subtitle:"From Basic Research to Clinical Applications",isOpenForSubmission:!1,hash:"8147834b6c6deeeec40f407c71ad60b4",slug:"electroencephalography-from-basic-research-to-clinical-applications",bookSignature:"Hideki Nakano",coverURL:"https://cdn.intechopen.com/books/images_new/9629.jpg",editedByType:"Edited by",editors:[{id:"196461",title:"Prof.",name:"Hideki",middleName:null,surname:"Nakano",slug:"hideki-nakano",fullName:"Hideki Nakano"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9685",title:"Agroecosystems",subtitle:"Very Complex Environmental Systems",isOpenForSubmission:!1,hash:"c44f7b43a9f9610c243dc32300d37df6",slug:"agroecosystems-very-complex-environmental-systems",bookSignature:"Marcelo L. Larramendy and Sonia Soloneski",coverURL:"https://cdn.intechopen.com/books/images_new/9685.jpg",editedByType:"Edited by",editors:[{id:"14764",title:"Dr.",name:"Marcelo L.",middleName:null,surname:"Larramendy",slug:"marcelo-l.-larramendy",fullName:"Marcelo L. Larramendy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9524",title:"Organ Donation and Transplantation",subtitle:null,isOpenForSubmission:!1,hash:"6ef47e03cd4e6476946fc28ca51de825",slug:"organ-donation-and-transplantation",bookSignature:"Vassil Mihaylov",coverURL:"https://cdn.intechopen.com/books/images_new/9524.jpg",editedByType:"Edited by",editors:[{id:"313113",title:"Associate Prof.",name:"Vassil",middleName:null,surname:"Mihaylov",slug:"vassil-mihaylov",fullName:"Vassil Mihaylov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9280",title:"Underwater Work",subtitle:null,isOpenForSubmission:!1,hash:"647b4270d937deae4a82f5702d1959ec",slug:"underwater-work",bookSignature:"Sérgio António Neves Lousada",coverURL:"https://cdn.intechopen.com/books/images_new/9280.jpg",editedByType:"Edited by",editors:[{id:"248645",title:"Dr.",name:"Sérgio António",middleName:null,surname:"Neves Lousada",slug:"sergio-antonio-neves-lousada",fullName:"Sérgio António Neves Lousada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9161",title:"Frailty in the Elderly",subtitle:"Understanding and Managing Complexity",isOpenForSubmission:!1,hash:"a4f0f2fade8fb8ba35c405f5ad31a823",slug:"frailty-in-the-elderly-understanding-and-managing-complexity",bookSignature:"Sara Palermo",coverURL:"https://cdn.intechopen.com/books/images_new/9161.jpg",editedByType:"Edited by",editors:[{id:"233998",title:"Ph.D.",name:"Sara",middleName:null,surname:"Palermo",slug:"sara-palermo",fullName:"Sara Palermo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8158",title:"Veganism",subtitle:"a Fashion Trend or Food as a Medicine",isOpenForSubmission:!1,hash:"d8e51fc25a379e5b92a270addbb4351d",slug:"veganism-a-fashion-trend-or-food-as-a-medicine",bookSignature:"Miljana Z. Jovandaric",coverURL:"https://cdn.intechopen.com/books/images_new/8158.jpg",editedByType:"Edited by",editors:[{id:"268043",title:"Dr.",name:"Miljana Z.",middleName:"Z",surname:"Jovandaric",slug:"miljana-z.-jovandaric",fullName:"Miljana Z. Jovandaric"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"22",title:"Robotics",slug:"physical-sciences-engineering-and-technology-robotics",parent:{title:"Physical Sciences, Engineering and Technology",slug:"physical-sciences-engineering-and-technology"},numberOfBooks:99,numberOfAuthorsAndEditors:1355,numberOfWosCitations:4163,numberOfCrossrefCitations:3113,numberOfDimensionsCitations:6196,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"physical-sciences-engineering-and-technology-robotics",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9902",title:"Service Robotics",subtitle:null,isOpenForSubmission:!1,hash:"9b42f533ea14906bcd1e07df74b33ac2",slug:"service-robotics",bookSignature:"Volkan Sezer, Sinan Öncü and Pınar Boyraz Baykas",coverURL:"https://cdn.intechopen.com/books/images_new/9902.jpg",editedByType:"Edited by",editors:[{id:"268170",title:"Dr.",name:"Volkan",middleName:null,surname:"Sezer",slug:"volkan-sezer",fullName:"Volkan Sezer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6864",title:"Autonomous Vehicles",subtitle:null,isOpenForSubmission:!1,hash:"c320902fc1cfc252c1db006b944996fb",slug:"autonomous-vehicles",bookSignature:"George Dekoulis",coverURL:"https://cdn.intechopen.com/books/images_new/6864.jpg",editedByType:"Edited by",editors:[{id:"9833",title:"Prof.",name:"George",middleName:null,surname:"Dekoulis",slug:"george-dekoulis",fullName:"George Dekoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8883",title:"Autonomous Vehicle and Smart Traffic",subtitle:null,isOpenForSubmission:!1,hash:"841c82c0bf27716a7c800bc1180ad5de",slug:"autonomous-vehicle-and-smart-traffic",bookSignature:"Sezgin Ersoy and Tayyab Waqar",coverURL:"https://cdn.intechopen.com/books/images_new/8883.jpg",editedByType:"Edited by",editors:[{id:"156004",title:"Associate Prof.",name:"Sezgin",middleName:null,surname:"Ersoy",slug:"sezgin-ersoy",fullName:"Sezgin Ersoy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8872",title:"Multi Agent Systems",subtitle:"Strategies and Applications",isOpenForSubmission:!1,hash:"6b0454f8f575d5d65603f329af59c80b",slug:"multi-agent-systems-strategies-and-applications",bookSignature:"Ricardo López - Ruiz",coverURL:"https://cdn.intechopen.com/books/images_new/8872.jpg",editedByType:"Edited by",editors:[{id:"9849",title:"Prof.",name:"Ricardo",middleName:null,surname:"Lopez-Ruiz",slug:"ricardo-lopez-ruiz",fullName:"Ricardo Lopez-Ruiz"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7792",title:"Unmanned Robotic Systems and Applications",subtitle:null,isOpenForSubmission:!1,hash:"53805f091c3107536edd2579c9987649",slug:"unmanned-robotic-systems-and-applications",bookSignature:"Mahmut Reyhanoglu and Geert De Cubber",coverURL:"https://cdn.intechopen.com/books/images_new/7792.jpg",editedByType:"Edited by",editors:[{id:"15068",title:"Dr.",name:"Mahmut",middleName:null,surname:"Reyhanoglu",slug:"mahmut-reyhanoglu",fullName:"Mahmut Reyhanoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6865",title:"Becoming Human with Humanoid",subtitle:"From Physical Interaction to Social Intelligence",isOpenForSubmission:!1,hash:"e208316a62e4ab5b042486aea682ee18",slug:"becoming-human-with-humanoid-from-physical-interaction-to-social-intelligence",bookSignature:"Ahmad Hoirul Basori, Ali Leylavi Shoushtari and Andon Venelinov Topalov",coverURL:"https://cdn.intechopen.com/books/images_new/6865.jpg",editedByType:"Edited by",editors:[{id:"13394",title:"Prof.",name:"Ahmad Hoirul",middleName:null,surname:"Basori",slug:"ahmad-hoirul-basori",fullName:"Ahmad Hoirul Basori"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7779",title:"Path Planning for Autonomous Vehicle",subtitle:"Ensuring Reliable Driverless Navigation and Control Maneuver",isOpenForSubmission:!1,hash:"91196f0aadb70bd5cecac290401d614f",slug:"path-planning-for-autonomous-vehicles-ensuring-reliable-driverless-navigation-and-control-maneuver",bookSignature:"Umar Zakir Abdul Hamid, Volkan Sezer, Bin Li, Yanjun Huang and Muhammad Aizzat Zakaria",coverURL:"https://cdn.intechopen.com/books/images_new/7779.jpg",editedByType:"Edited by",editors:[{id:"268173",title:"Dr.",name:"Umar Zakir Abdul",middleName:null,surname:"Hamid",slug:"umar-zakir-abdul-hamid",fullName:"Umar Zakir Abdul Hamid"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7386",title:"Advances in Human and Machine Navigation Systems",subtitle:null,isOpenForSubmission:!1,hash:"a60a4da048a8bee2e12c3fe40236afe9",slug:"advances-in-human-and-machine-navigation-systems",bookSignature:"Rastislav Róka",coverURL:"https://cdn.intechopen.com/books/images_new/7386.jpg",editedByType:"Edited by",editors:[{id:"112777",title:"Dr.",name:"Rastislav",middleName:null,surname:"Róka",slug:"rastislav-roka",fullName:"Rastislav Róka"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7227",title:"Applications of Mobile Robots",subtitle:null,isOpenForSubmission:!1,hash:"b4993517c29aed9abd474e362370e28a",slug:"applications-of-mobile-robots",bookSignature:"Efren Gorrostieta Hurtado",coverURL:"https://cdn.intechopen.com/books/images_new/7227.jpg",editedByType:"Edited by",editors:[{id:"38850",title:"Dr.",name:"Efren",middleName:null,surname:"Gorrostieta Hurtado",slug:"efren-gorrostieta-hurtado",fullName:"Efren Gorrostieta Hurtado"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7400",title:"Multi-Agent Systems",subtitle:"Control Spectrum",isOpenForSubmission:!1,hash:"ba8de13ac5162187fbc7f932a7fb0b34",slug:"multi-agent-systems-control-spectrum",bookSignature:"Vladimir Shikhin",coverURL:"https://cdn.intechopen.com/books/images_new/7400.jpg",editedByType:"Edited by",editors:[{id:"237011",title:"Dr.",name:"Vladimir",middleName:null,surname:"Shikhin",slug:"vladimir-shikhin",fullName:"Vladimir Shikhin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7270",title:"Agricultural Robots",subtitle:"Fundamentals and Applications",isOpenForSubmission:!1,hash:"404b9128ab371832f2b7f0b6f32b2951",slug:"agricultural-robots-fundamentals-and-applications",bookSignature:"Jun Zhou and Baohua Zhang",coverURL:"https://cdn.intechopen.com/books/images_new/7270.jpg",editedByType:"Edited by",editors:[{id:"242047",title:"Dr.",name:"Jun",middleName:null,surname:"Zhou",slug:"jun-zhou",fullName:"Jun Zhou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6322",title:"Advanced Path Planning for Mobile Entities",subtitle:null,isOpenForSubmission:!1,hash:"438f519ccb7ac4196660ada6b648e15f",slug:"advanced-path-planning-for-mobile-entities",bookSignature:"Rastislav Róka",coverURL:"https://cdn.intechopen.com/books/images_new/6322.jpg",editedByType:"Edited by",editors:[{id:"112777",title:"Dr.",name:"Rastislav",middleName:null,surname:"Róka",slug:"rastislav-roka",fullName:"Rastislav Róka"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:99,mostCitedChapters:[{id:"10088",doi:"10.5772/8835",title:"Intention-Based Walking Support for Paraplegia Patients with Robot Suit HAL",slug:"intention-based-walking-support-for-paraplegia-patients-with-robot-suit-hal",totalDownloads:4811,totalCrossrefCites:15,totalDimensionsCites:165,book:{slug:"climbing-and-walking-robots",title:"Climbing and Walking Robots",fullTitle:"Climbing and Walking Robots"},signatures:"Kenta Suzuki, Gouji Mito, Hiroaki Kawamoto, Yasuhisa Hasegawa and Yoshiyuki Sankai",authors:null},{id:"240",doi:"10.5772/4876",title:"Geminoid: Teleoperated Android of an Existing Person",slug:"geminoid__teleoperated_android_of_an_existing_person",totalDownloads:3914,totalCrossrefCites:63,totalDimensionsCites:115,book:{slug:"humanoid_robots_new_developments",title:"Humanoid Robots",fullTitle:"Humanoid Robots: New Developments"},signatures:"Shuichi Nishio, Hiroshi Ishiguro and Norihiro Hagita",authors:[{id:"11981",title:"Prof.",name:"Hiroshi",middleName:null,surname:"Ishiguro",slug:"hiroshi-ishiguro",fullName:"Hiroshi Ishiguro"}]},{id:"172",doi:"10.5772/4808",title:"Limit Cycle Walking",slug:"limit_cycle_walking",totalDownloads:4631,totalCrossrefCites:9,totalDimensionsCites:92,book:{slug:"humanoid_robots_human_like_machines",title:"Humanoid Robots",fullTitle:"Humanoid Robots, Human-like Machines"},signatures:"Daan G.E. Hobbelen and Martijn Wisse",authors:null}],mostDownloadedChaptersLast30Days:[{id:"10088",title:"Intention-Based Walking Support for Paraplegia Patients with Robot Suit HAL",slug:"intention-based-walking-support-for-paraplegia-patients-with-robot-suit-hal",totalDownloads:4813,totalCrossrefCites:15,totalDimensionsCites:165,book:{slug:"climbing-and-walking-robots",title:"Climbing and Walking Robots",fullTitle:"Climbing and Walking Robots"},signatures:"Kenta Suzuki, Gouji Mito, Hiroaki Kawamoto, Yasuhisa Hasegawa and Yoshiyuki Sankai",authors:null},{id:"67705",title:"Advanced UAVs Nonlinear Control Systems and Applications",slug:"advanced-uavs-nonlinear-control-systems-and-applications",totalDownloads:1124,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"unmanned-robotic-systems-and-applications",title:"Unmanned Robotic Systems and Applications",fullTitle:"Unmanned Robotic Systems and Applications"},signatures:"Abdulkader Joukhadar, Mohammad Alchehabi and Adnan Jejeh",authors:null},{id:"63775",title:"Fundamental Research on Unmanned Aerial Vehicles to Support Precision Agriculture in Oil Palm Plantations",slug:"fundamental-research-on-unmanned-aerial-vehicles-to-support-precision-agriculture-in-oil-palm-planta",totalDownloads:2064,totalCrossrefCites:2,totalDimensionsCites:13,book:{slug:"agricultural-robots-fundamentals-and-applications",title:"Agricultural Robots",fullTitle:"Agricultural Robots - Fundamentals and Applications"},signatures:"Redmond Ramin Shamshiri, Ibrahim A. Hameed, Siva K. Balasundram, Desa Ahmad, Cornelia Weltzien and Muhammad Yamin",authors:[{id:"182449",title:"Prof.",name:"Ibrahim",middleName:null,surname:"A. Hameed",slug:"ibrahim-a.-hameed",fullName:"Ibrahim A. Hameed"},{id:"203413",title:"Dr.",name:"Redmond Ramin",middleName:null,surname:"Shamshiri",slug:"redmond-ramin-shamshiri",fullName:"Redmond Ramin Shamshiri"}]},{id:"51224",title:"Series Elastic Actuator: Design, Analysis and Comparison",slug:"series-elastic-actuator-design-analysis-and-comparison",totalDownloads:2700,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"recent-advances-in-robotic-systems",title:"Recent Advances in Robotic Systems",fullTitle:"Recent Advances in Robotic Systems"},signatures:"Arnaldo Gomes Leal Junior, Rafhael Milanezi de Andrade and\nAntônio Bento Filho",authors:[{id:"182082",title:"Dr.",name:"Rafhael",middleName:"Milanezi De",surname:"Andrade",slug:"rafhael-andrade",fullName:"Rafhael Andrade"},{id:"185372",title:"Dr.",name:"Antônio",middleName:null,surname:"Bento Filho",slug:"antonio-bento-filho",fullName:"Antônio Bento Filho"},{id:"185373",title:"MSc.",name:"Arnaldo",middleName:null,surname:"Gomes Leal Junior",slug:"arnaldo-gomes-leal-junior",fullName:"Arnaldo Gomes Leal Junior"}]},{id:"62978",title:"Intelligent Robotic Perception Systems",slug:"intelligent-robotic-perception-systems",totalDownloads:1389,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"applications-of-mobile-robots",title:"Applications of Mobile Robots",fullTitle:"Applications of Mobile Robots"},signatures:"Cristiano Premebida, Rares Ambrus and Zoltan-Csaba Marton",authors:[{id:"203409",title:"Ph.D.",name:"Cristiano",middleName:null,surname:"Premebida",slug:"cristiano-premebida",fullName:"Cristiano Premebida"},{id:"254880",title:"Dr.",name:"Rares",middleName:null,surname:"Ambrus",slug:"rares-ambrus",fullName:"Rares Ambrus"},{id:"254881",title:"Dr.",name:"Zoltan-Csaba",middleName:null,surname:"Marton",slug:"zoltan-csaba-marton",fullName:"Zoltan-Csaba Marton"}]},{id:"56737",title:"UAV for Landmine Detection Using SDR-Based GPR Technology",slug:"uav-for-landmine-detection-using-sdr-based-gpr-technology",totalDownloads:2514,totalCrossrefCites:6,totalDimensionsCites:7,book:{slug:"robots-operating-in-hazardous-environments",title:"Robots Operating in Hazardous Environments",fullTitle:"Robots Operating in Hazardous Environments"},signatures:"Manuel Ricardo Pérez Cerquera, Julian David Colorado Montaño\nand Iván Mondragón",authors:[{id:"177422",title:"Dr.",name:"Julian",middleName:null,surname:"Colorado",slug:"julian-colorado",fullName:"Julian Colorado"},{id:"197884",title:"Prof.",name:"Ivan",middleName:null,surname:"Mondragon",slug:"ivan-mondragon",fullName:"Ivan Mondragon"},{id:"199958",title:"Prof.",name:"Manuel",middleName:null,surname:"Perez",slug:"manuel-perez",fullName:"Manuel Perez"}]},{id:"70496",title:"Sky-Farmers: Applications of Unmanned Aerial Vehicles (UAV) in Agriculture",slug:"sky-farmers-applications-of-unmanned-aerial-vehicles-uav-in-agriculture",totalDownloads:911,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"autonomous-vehicles",title:"Autonomous Vehicles",fullTitle:"Autonomous Vehicles"},signatures:"Chika Yinka-Banjo and Olasupo Ajayi",authors:null},{id:"56199",title:"Robots in Agriculture: State of Art and Practical Experiences",slug:"robots-in-agriculture-state-of-art-and-practical-experiences",totalDownloads:2591,totalCrossrefCites:25,totalDimensionsCites:37,book:{slug:"service-robots",title:"Service Robots",fullTitle:"Service Robots"},signatures:"Juan Jesús Roldán, Jaime del Cerro, David Garzón‐Ramos, Pablo\nGarcia‐Aunon, Mario Garzón, Jorge de León and Antonio Barrientos",authors:[{id:"130776",title:"Prof.",name:"Antonio",middleName:null,surname:"Barrientos Cruz",slug:"antonio-barrientos-cruz",fullName:"Antonio Barrientos Cruz"},{id:"162360",title:"Dr.",name:"Jaime",middleName:null,surname:"Del Cerro",slug:"jaime-del-cerro",fullName:"Jaime Del Cerro"},{id:"199008",title:"M.Sc.",name:"Juan Jesús",middleName:null,surname:"Roldán",slug:"juan-jesus-roldan",fullName:"Juan Jesús Roldán"},{id:"199515",title:"MSc.",name:"Mario",middleName:null,surname:"Garzón",slug:"mario-garzon",fullName:"Mario Garzón"},{id:"199517",title:"MSc.",name:"David",middleName:null,surname:"Garzón",slug:"david-garzon",fullName:"David Garzón"},{id:"199518",title:"MSc.",name:"Jorge",middleName:null,surname:"De León",slug:"jorge-de-leon",fullName:"Jorge De León"},{id:"199519",title:"MSc.",name:"Pablo",middleName:null,surname:"Garcia-Aunon",slug:"pablo-garcia-aunon",fullName:"Pablo Garcia-Aunon"}]},{id:"5555",title:"Trends in Robotics and Automation in Construction",slug:"trends_in_robotics_and_automation_in_construction",totalDownloads:18155,totalCrossrefCites:15,totalDimensionsCites:34,book:{slug:"robotics_and_automation_in_construction",title:"Robotics and Automation in Construction",fullTitle:"Robotics and Automation in Construction"},signatures:"Carlos Balaguer and Mohamed Abderrahim",authors:null},{id:"73486",title:"Application of Artificial Intelligence (AI) in Prosthetic and Orthotic Rehabilitation",slug:"application-of-artificial-intelligence-ai-in-prosthetic-and-orthotic-rehabilitation",totalDownloads:460,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"service-robotics",title:"Service Robotics",fullTitle:"Service Robotics"},signatures:"Smita Nayak and Rajesh Kumar Das",authors:[{id:"204704",title:"Mrs.",name:"Smita",middleName:null,surname:"Nayak",slug:"smita-nayak",fullName:"Smita Nayak"},{id:"321308",title:"Dr.",name:"Rajesh",middleName:null,surname:"Das",slug:"rajesh-das",fullName:"Rajesh Das"}]}],onlineFirstChaptersFilter:{topicSlug:"physical-sciences-engineering-and-technology-robotics",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"75911",title:"QoS Control in Remote Robot Operation with Force Feedback",slug:"qos-control-in-remote-robot-operation-with-force-feedback",totalDownloads:9,totalDimensionsCites:0,doi:"10.5772/intechopen.97011",book:{title:"Robotics Software Design and Engineering"},signatures:"Pingguo Huang and Yutaka Ishibashi"},{id:"76036",title:"Use Improved Differential Evolution Algorithms to Handle the Inverse Kinetics Problem for Robots with Residual Degrees of Freedom",slug:"use-improved-differential-evolution-algorithms-to-handle-the-inverse-kinetics-problem-for-robots-wit",totalDownloads:16,totalDimensionsCites:0,doi:"10.5772/intechopen.97138",book:{title:"Robotics Software Design and Engineering"},signatures:"Trung Nguyen and Tam Bui"},{id:"75836",title:"Self-Learning Low-Level Controllers",slug:"self-learning-low-level-controllers",totalDownloads:31,totalDimensionsCites:0,doi:"10.5772/intechopen.96732",book:{title:"Humanoid Robots"},signatures:"Dang Xuan Ba and Joonbum Bae"}],onlineFirstChaptersTotal:7},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/298488/carlos-coutinho",hash:"",query:{},params:{id:"298488",slug:"carlos-coutinho"},fullPath:"/profiles/298488/carlos-coutinho",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()